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ISOFORM SELECTIVE REGULATION OF ADENYLYL CYCLASE BY SMALL 
MOLECULE INHIBITORS AND Gβγ PROTEIN 
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The nine membrane-bound isoforms of adenylyl cyclase (AC), via synthesis of the 
signaling molecule cyclic AMP (cAMP), are involved in many isoform specific physiological 
functions. All nine isoforms share a similar structural organization; thus, AC isoform 
differences in physiological function are due to different regulatory profiles. A physiological 
example is Gβγ, which can conditionally enhance stimulation of ACs 2, 4, 5, 6, and 7, but 
inhibit ACs 1, 3, and 8. There is also pharmacological control of AC isoforms through small 
molecule inhibitors. 
Isoform specific AC functions could be explained by regulatory differences as subtle as 
single amino acid changes. For both pharmacological targeting and known physiological 
regulators, differences between isoforms are not well understood. Two approaches were taken 
to explore AC5/6 isoform selectivity. The first approach was to more completely characterize 
allegedly AC5 selective small molecule AC inhibitors. The other approach was to examine AC 
isoform regulation by Gβγ. 
The AC inhibitors SQ22,536 and Ara-A, rather than being AC5 selective as previously 
described, are AC5/6 inhibitors. Another AC inhibitor, NB001, showed AC1-dependent 
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decreases in cAMP within cells without directly inhibiting AC1. These results highlighted the 
importance of AC inhibitor characterizations for AC specificity and isoform selectivity. 
Gβγ regulation of AC5/6 was also explored. We showed that Gβγ binds to many AC N-
termini (NT), but only AC5 NT binding did not require the Gβγ “hotspot”, a surface involved 
in many Gβγ regulatory events. Mutations of the hotspot showed it was necessary for AC5 
stimulation but not AC5 NT binding. In contrast, the hotspot was required for both AC6 NT 
binding and AC6 stimulation. Peptide competition to disrupt Gβγ hotspot dependent binding 
events affected regulation of AC1/2/6 by Gβγ, but not that of AC5. Gβγ also interacted with 
both the AC5/6 C1/C2 catalytic domains, with similar hotspot dependency. This work 
suggested that Gβγ stimulation of AC5/6 occurs in a similar hotspot-dependent binding event, 
but that Gβγ/AC5NT binding is an isoform specific G protein anchoring event. 
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Lay Abstract 
Adenylyl cyclase (AC) is a protein that allows signals from outside the cell to be 
transferred into the cell. There are nine types of AC that, despite being structurally similar, 
have differences in their functions. For example, just a single one of the nine AC types is 
involved in aspects of heart function, pain sensation, and dependency/withdrawal behaviors 
from the use of opioids such as morphine. The other AC types have additional, and sometimes 
overlapping, functions. This makes it important to know how each type of AC is controlled, 
both for explaining specific biological effects from AC signaling and for selective targeting 
with drug treatments while limiting side effects. 
Since the nine AC types are controlled differently despite similar structures, selective 
control of AC activity is explained by subtle differences. For both drugs and proteins that 
control AC, many such differences are not well understood. Some AC-targeting drugs which 
were possible treatments to prevent heart failure have been incorrectly described previously as 
able to selectively decrease the activity of a single AC type. My studies indicated that these 
drugs also affect another AC type which causes increased risk of heart failure. I also studied the 
effects of a signaling protein on two closely related AC types. This signaling protein was able 
to increase activity of both AC types; however, only one had a unique spot for this signaling 
protein to remain anchored nearby. Overall, my studies clarified differential targeting of AC 
types by drugs, and the potential importance of a site that is unique for how one AC type is 
controlled. 
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Chapter 1 
Introduction 
 
1.1 Adenylyl Cyclase/Cyclic AMP Signaling 
Adenylyl cyclase (AC) is an enzyme that converts adenosine triphosphate (ATP) into 
cyclic adenosine monophosphate (cAMP) and pyrophosphate (3). Within cells, cAMP 
produced by AC is a 2nd messenger that activates downstream signaling partners such as PKA 
and EPAC (4, 5), resulting in a variety of cellular signaling functions (6). Such cAMP signaling 
can be attenuated via degradation of the produced cAMP by phosphodiesterases (7, 8).  
AC is a bottleneck enzyme for cAMP signaling pathways; cardiomyocytes have about 
4.7 × 106 Gαs within the cell, but can only form 6 × 105 Gαs/AC signaling complexes upon G 
protein activation (9). Thus, AC activity is an important control node in signal transduction via 
pathways that use cAMP as a 2nd messenger. In mammals, there are nine membrane-bound AC 
isoforms (AC1-9), and a soluble isoform (sAC) that is more closely related to bacterial cyclases 
(10). The number of isoforms, or subtypes of the AC enzyme with the same cAMP-producing 
capability, varies by species.  
 
1.2 AC Structure 
In addition to catalyzing production of cAMP, AC1-9 also share a common overall 
structure (Figure 1A). This structure involves three cytosolic domains separated by a pair of 6-
transmembrane helical domains; an N-terminus (NT), and two cytosolic domains (C1 and C2) 
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that comprise the catalytic site where ATP conversion to cAMP takes place (11). These 
cytosolic domains are also where Gαs and Gαi bind to stimulate or inhibit AC activity. The 
C1/C2 domains have roughly 40% sequence homology, and are pseudosymmetric. Crystal 
structures indicate that the catalytic site of AC is located at the C1/C2 domain interface, with 
each domain forming one half of a shell-like structure that can be accessed from the cytoplasm 
(12). There is also similarity between the C1/C2 domains of adenylyl cyclase and the guanylyl 
cyclase catalytic domains (11). Whereas the C1/C2 domains have 40% homology across AC1-
9, the NT domain differs much more among isoforms in both amino acid sequence and length. 
 
 
1.3 AC Regulation 
 Various regulatory proteins interact directly with AC in order to increase or decrease 
AC activity, and thus control AC/cAMP signaling. AC isoforms have been categorized based 
on shared regulators as Group I (AC1/3/8), Group II (AC 2/4/7), Group III (AC5/6), and Group 
IV (AC9). These groups can also be formed based on phylogenic comparisons of the isoforms 
Figure 1: Adenylyl Cyclase Structure. A, Overall structural organization of transmembrane 
adenylyl cyclase. Three cytoplasmic domains (NT, C1, C2) are separated by a pair of 6-
transmembrane domains. B, Crystal structure (from PDB 1CJT) of the C1/C2 domains from the 
cytoplasmic view, with the ATP-binding site indicated. Rendered with VMD. 
3 
 
(13). Group I isoforms share stimulation by calcium-activated calmodulin (14-17). Group II 
isoforms have considerable stimulation by Gβγ (18-21). Group III isoforms have sensitive, sub-
micromolar level inhibition by free calcium (22), as well as inhibition by Gαi (23, 24). AC9 is 
set aside solely as Group IV, with a unique regulatory profile including less sequence 
homology relative to AC1-8 and insensitivity to the AC activator forskolin (25). Regulators of 
AC bind to the C1/C2 domains to directly modify AC activity, or alternatively bind at the NT 
for regulatory effect. 
 The most thoroughly studied physiological regulators of AC activity are the 
heterotrimeric G proteins. The heterotrimer consists of a guanine nucleotide binding α subunit, 
and an obligate βγ subunit heterodimer. Under classic G protein signaling, these subunits are 
held in an inactive heterotrimer by GDP-bound Gα. Following upstream Gα activation via 
exchange of GDP for GTP by ligand-bound G protein coupled receptors (GPCRs), these 
subunits dissociate, allowing for regulation of downstream targets such as AC (26). In some 
cases, these subunits may rearrange to expose regulatory sites rather than full dissociation 
taking place (27). This has been shown in FRET-based studies where GPCR activation resulted 
in rearrangement, but not dissociation, of Gαi and Gβγ (28, 29). Differential models for Gαs 
stimulation of AC1/2/6 suggest that the mechanisms of AC stimulation by a heterotrimeric G 
protein subunit may vary among AC isoforms, even when the regulatory effect on AC activity 
is the same (30). Characterization of AC5/6 regulation by Gα subunits has resulted in similar 
conclusions (23). Gαs stimulates all AC isoforms, while Gαi inhibits AC1/5/6 (23, 24, 31). 
These Gα subunit types were named “s” and “i” due to their respective stimulatory or inhibitory 
effects on AC activity. Gαi inhibits AC isoforms via binding to C1 in a site pseudosymmetrical 
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to that on C2 for Gαs (32). Furthermore, Gαz inhibits AC1/5/6 (33), while Gαo inhibits AC1 
(34). 
Gβγ subunits have more differential, AC isoform dependent effects. Gβγ can 
conditionally stimulate AC2/4/5/6/7 in the presence of Gαs or forskolin (18-21, 35), but inhibits 
the activity of AC1/3/8 (18, 36, 37). Thus, heterotrimeric G protein activation has the potential 
to either stimulate or inhibit AC activity, depending on the particular Gα subunit and the 
resulting target of the freed Gβγ subunits.  
Heterotrimeric G proteins are not the only significant AC regulators. For example, 
differential effects on AC isoforms by kinase phosphorylation have been described. Although 
PKA is activated by cAMP, feedback inhibition from PKA has also been observed for AC5/6 
and AC8, phosphorylating the C1 domain in a region required for Gαs stimulation of AC6 (38, 
39). PKC has both stimulatory and inhibitory regulations on AC that are specific to particular 
combinations of both AC isoform and PKC isoform (40). There is also stimulation of AC1/3/8 
by calmodulin and inhibition of AC5/6 by free calcium as mentioned previously (14-17). 
Free calcium ions, in addition to inhibiting AC5/6 via a high-affinity binding site with a 
Ki of 0.2 μM, are capable of inhibiting all other AC isoforms at higher concentrations via a 
low-affinity binding site with a Ki of 100 μM (22, 41). In both cases, calcium inhibition of AC 
is via competition with Mg2+ at the catalytic site. This is because AC catalysis requires Mg2+ or 
Mn2+ to facilitate phosphate transfer; Zn2+ can also inhibit AC in a mechanism similar to that of 
Ca2+, emphasizing the various metal ions with regulatory effects on AC activity (42-44).  
Of note is the AC stimulator forskolin, a diterpene derived from the root of the plant 
Coleus forskohlii (45). It is able to clearly stimulate activity of all the membrane-bound AC 
isoforms except AC9 (25, 46), and is used frequently in research studying cAMP signaling 
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pathways for this purpose. A single forskolin molecule binds at the interface of the C1 and C2 
domains, and its affinity increases with Gαs stimulation of AC (47). Due to the 
pseudosymmetrical structure of C1/C2, the forskolin binding pocket is structurally related to 
the ATP-binding active site. However, the evolutionary reason for this molecule’s evolved 
binding site being so conserved is unclear. Although AC9 is considered to be forskolin-
insensitive, this may just be due to a large negative shift in forskolin affinity; mutation of a key 
residue within the forskolin-binding pocket can elevate AC9’s forskolin sensitivity to the level 
exhibited by the other AC isoforms (48). Thus, AC isoforms have many potential regulatory 
stimuli; notable regulators of AC isoforms are summarized in Table 1. This wide variety of 
potential regulators results in a complex picture for how AC activity is tightly controlled. 
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Table 1: Regulatory Properties of Adenylyl Cyclase Isoforms 
Regulator 
Regulatory Effect 
Group I Group II Group III Group 
IV 
AC1 AC3 AC8 AC2 AC4 AC7 AC5 AC6 AC9 
Gαs ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 
Gαi ↓      ↓ ↓  
Gαo ↓         
Gαz ↓      ↓ ↓  
Gβγ ↓ ↓ ↓ ↑ ↑ ↑ ↑ ↑  
PKA   ↓    ↓ ↓  
PKC 
↑ 
(α) 
↑ 
(α) 
 ↑ 
(α) 
↓ 
(α) 
↑ 
(α) 
↑ 
(α, ζ) 
↓ 
(δ, ε) 
 
CaM ↑ ↑ ↑       
Ca2+       ↓ ↓  
CaMK 
↓ 
(CaMK IV) 
↓ 
(CaMK II) 
       
CaN         ↓ 
Forskolin ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑  
↑ = stimulation, ↓ = inhibition. PKC, calmodulin kinase (CaMK) isoforms are as indicated. 
 
 
1.4 Gβγ Activation and Regulation of Effectors 
There are five Gβ and 12 Gγ subunit isoforms. Gβ1-4 share over 80% sequence 
similarity, and along with the 12 Gγ isoforms are considered to have similar effects on 
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regulatory targets. Studies on the Gβγ isoform combinations, and whether they have differential 
signaling effects, have shown that various combinations of β and γ subunits are typically 
similar in how they interact with effector targets (35). For example, β1γ2, β1γ3, β2γ2, and β2γ3 
all show inhibition of AC1, stimulation of AC2, and similar rates of associated Gαo ADP-
ribosylation, with slight differences in their rates of associated Gαi ADP-ribosylation (35). A 
notable exception is Gβ1γ1, known as the signaling Gβγ involved in the retina. Complexes 
containing γ1 are consistently expressed in the retina for signaling with the Gα transducin, and 
are less potent at regulating AC and PLC isoforms (35, 49). When different Gβγ dimer 
combinations were tested in Gαi-coupled GPCR mediated inhibition of AC8, the effect was 
AC8 inhibition, although potency of this inhibitory effect varied between Gβγ isoforms (50). 
Thus, based on currently published work, the regulatory effect of Gβγ on AC is dependent on 
the AC isoform but not the Gβγ isoforms, as long as the Gβ subunit is 1-4. 
As mentioned above, Gβγ subunits are an interesting case of isoform specific AC 
regulation, stimulating AC2/4/5/6/7 with Gαs (18-21, 35), but inhibiting AC1/3/8 (18, 36, 37). 
For AC/Gβγ binding, there appears to be a lack of conserved interaction sites, even between 
closely related AC isoforms. Using a combination of peptide probes and molecular modeling, it 
was identified that aa 956-982 in the AC2 C2 domain bound to the Gβγ hotspot (51-53). Four 
other Gβγ hotspot binding sites have also been identified on the C1/C2 domains of AC2, 
suggesting binding between Gβγ and AC involves multiple interactions and/or different binding 
sites for Gβγ regulatory function (36, 54, 55). 
In addition to AC, Gβγ has a significant number of effectors it can regulate. Most 
notable is Gβγ regulation that stimulates opening of GIRK channels (56-58). Regulation by Gαi 
and Gβγ and their mechanisms of differential GIRK channel regulation have been extensively 
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studied (59-69). Gβγ can also bind to GRK2 and GRK3, recruit them to the plasma membrane, 
and facilitate GRK phosphorylation, β-arrestin recruitment, and internalization of β-adrenergic 
receptors (70, 71). Gβγ is also capable of binding to and directly activating PLCβ1-3; for all 
isoforms, this is a Gα-independent regulatory capability of Gβγ (72-76). Direct opening of 
calcium channels can also be regulated by Gβγ independently of Gα (despite Gα binding sites), 
such as N-type, P-type, and Q-type voltage gated calcium channels (77-80). Although 
sensitivity is dependent on adapter proteins, Gβγ can also bind and activate PI3K isoforms (81, 
82). Gβγ is able to negatively regulate SNARE protein mediated vesicle formation via its 
interaction with SNAP25, most notably to inhibit presynaptic neurotransmitter release (83, 84). 
Gβγ is also able to stimulate GEFs that function downstream of heterotrimeric G protein 
signaling, such as P-Rex1 (85). In summary, Gβγ is like AC in that it has an endless list of 
proteins it regulates through indirect pathways or downstream effects. Thus, Gβγ regulation of 
AC is not only important for modulating cAMP production, but AC may also compete with 
other potential effector targets of Gβγ. 
While GPCR signaling tends to activate Gα subunits through catalyzing GDP-to-GTP 
exchange, it appears that Gβγ is required for the plasma membrane association that is needed 
for Gα/GPCR coupling (86). Gβγ can bind to GPCRs, but mutation of the Gβγ binding site on 
M3 muscarinic receptor prevented receptor desensitization and not downstream signaling; thus, 
it is possible that Gβγ/GPCR direct binding events are involved in recruitment of 
desensitization signal proteins such as GRK more so than GPCR/G protein/AC/cAMP 
signaling events (87). 
Lacking any enzymatic activation through nucleotide exchange like its Gα counterparts, 
Gβγ activation occurs through the dissociation and/or rearrangement caused by activation of its 
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associated Gα subunit. Crystal structures indicate minimal structural changes to the Gβγ 
subunit in the absence versus presence of Gαi (88, 89). Switch II of Gαi covers a particular 
surface of Gβγ in the heterotrimer conformation, namely the intersection of the Gβ structural 
blades (88). This so called Gβ “hotspot” is covered by Gα (Figure 2), and when exposed is 
capable of interacting with a variety of effectors; alanine substitution mutants have shown 
previously that interference with individual hotspot residues have differential yet overlapping 
effects on Gβγ regulation of a wide variety of downstream effector targets, including AC (90, 
91). However, while hiding the hotspot appears to determine activation of Gβγ from an inactive 
heterotrimer, there are other surfaces down the blades of the Gβ propeller type structure that are 
also associated in Gβγ/effector interactions. This has most clearly been shown for Gβγ 
regulation of PLCβ (92).  
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1.5 NT Roles in AC Regulation 
The AC NT has known regulatory roles, many of which are isoform-specific. NT 
domains of AC 5, 6, and 8 bind Gβγ (93, 94). A binding site for inactive G protein heterotrimer 
on the AC 5NT was previously identified at residues 66-137, with synergistic binding enhanced 
by the presence of both subunits (95). The 6NT binds Gβγ at residues 77-151 (93). A large 
number of PKC isoforms have been identified to have AC NT binding sites, including a 
possible PKC inhibition site at Ser10 on 6NT (96). The 6NT binds with Snapin, a SNARE 
complex associated protein that also was capable of blocking PKC inhibition of AC6 when 
bound (97). The 5NT associates with the guanine nucleotide exchange factor Ric8a (98). 8NT 
binds the phosphatase PP2A (94). Some AC NT have also had identified or proposed 
Figure 2: Gβ Hotspot Covered by Inactive G Protein Heterotrimer. From 
crystal structure of inactive Gαi/β1/γ2 protein heterotrimer (PDB 1GP2). 
Hotspot residues mutated in shown results (see Chapter 4) are indicated in 
red. Gα is blue, Gβ is green, and Gγ is yellow as are indicated. 
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mechanisms of regulatory action on the activity of their particular AC. 5NT takes part in RGS2 
regulation of AC5 (99), 6NT is involved in Gαi inhibition of AC6 (100), and 8NT facilitates 
AC8 stimulation by calmodulin (101). 
The NT of AC isoforms also mediate larger AC/cAMP signaling complexes. Typically, 
this has been done through interactions with the large A-Kinase Anchoring Proteins (AKAPs) 
that facilitate control of AC activity. This is primarily by providing a link between AC and 
PKA, but other kinases, phosphatases, and phosphodiesterases that can potentially modulate 
AC activity or cAMP accumulation can also be associated with an AC isoform via an AKAP 
complex. The AC2 NT can bind to the AKAP Yotiao; in the brain, this AC2/Yotiao interaction 
decreased cAMP production (102). The AC5/6/9 NT can interact with AKAP79, including 
mediating PKA feedback inhibition of AC5/6 (103, 104). Notably, a peptide blocking 
AC5/AKAP79 interactions but not disrupting other AC/AKAP complexes can specifically 
disrupt PKA feedback inhibition of AC5 (104). The AC5/AKAP79 complex is also capable of 
mediating AC/cAMP signaling that locally activates the TRPV1 channel, which can direct a 
sensitized response to thermal pain signaling (105-108). The AC9 NT interacts with Yotiao, 
linking AC9 and the KCNQ1 channel in a complex associated with cardiac repolarization (109-
111). AC5 NT interacts with mAKAPβ as part of a hypertrophic signaling complex at the 
nuclear membrane of cardiomyocytes; similar to AC5/AKAP79 complexes, specific disruption 
of the AC5/mAKAPβ complex blocks hypertrophic effects (112-114). Thus, via AKAP 
interactions, the AC NT is involved in the constitution of isoform specific signal complexes. 
 
1.6 AC5 and AC6 Isoforms 
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The Group III AC isoforms, AC5/6, are the most closely related isoforms with many 
shared regulators, yet also display differences in their regulation and physiological function. 
AC5/6 are both stimulated by Gαs and Gβγ (93). They are also both directly inhibited by Gαi 
(24), Ca2+ (22, 41), and PKA(38). However, while Gαs stimulated activity of either isoform is 
inhibited by Gαi, only basal activity of AC5 is also inhibited by Gαi (23). AC5/6 are both 
indirectly inhibited by Gαo (115). There is also diversity in PKC isoform effects between AC5 
and AC6. Specifically, AC5 is directly stimulated by PKC-α and –ζ (40, 116), while AC6 is 
directly inhibited by PKC-δ and –ε (117, 118). Indirect regulatory effects on AC via Gαq 
signaling can enhance AC6 activity, but not that of AC5, within intact cells by a 
calcium/calmodulin dependent mechanism (119). 
The regulation of AC5 and AC6 by Gβγ differs in several respects to that of AC2. In 
response to Gαs-coupled receptor activation, both heterotrimeric G protein subunits are needed 
to observe a full stimulatory AC6 response (93), while Gβγ stimulation of AC 2/4/7 is thought 
to occur via activation of Gαi-coupled receptors (19). This suggests unique functions for Gβγ 
regulation of the AC5/6 isoforms.  Gβγ can activate AC 2, 5 and 6 in the presence of either Gαs 
or forskolin, but has no effect on basal AC activity (93). Prenylation of the γ subunit was also 
necessary, which suggests Gβγ stimulation of AC isoforms requires an interaction at the plasma 
membrane. Gαs and forskolin are also capable of simultaneous stimulation of AC; whether this 
stimulation is synergistic or additive is isoform specific (46).  
The “similar yet different” aspects of AC5/6 are reflected in their physiological 
distribution and roles. Both isoforms are expressed in the heart, brain, kidney, liver, lung, testis, 
and adrenal gland, but not always at equal levels. For example, while AC5/6 are the 
predominant AC isoforms in the heart (120), neonates express AC6 as the predominant isoform 
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while adult hearts have an increase in the relative levels of AC5 expression (121). Specific 
locations of expression in the same organ also can vary. AC5 expression has been shown 
mainly in the left ventricle while AC6 is located in both the left ventricle and atria (122). In the 
striatum region of the brain, which is involved in locomotor function, AC5 is highly expressed 
compared to other AC isoforms (123). AC5 in the striatum is also involved in D2 dopamine 
receptor mediated responses, learning, anxiety, and morphine action (123-126). 
Potential therapeutic benefit from AC5/6 modulation has shown unique differences 
between the isoforms in knockout models. AC5 knockout models indicate roles for AC5 
behaviors resulting from chronic opioid use (126), and similar AC5-dependent signaling 
pathways are involved in mechanical and inflammatory pain sensation (127). AC5 knockout 
models also show a protective phenotype against chronic heart failure (128-130). Deletion of 
AC5 also has anti-aging cardiac benefits (131). Due to these AC5 KO phenotypes, selective 
inhibition of AC5 is a proposed treatment target against chronic heart failure (132-134). 
However, cardiac homogenates or myocardial isolations from failing human hearts have 
decreased basal cAMP levels, as well as impaired cAMP production when faced with 
responding to adrenergic stimulation (135, 136). Further complicating the picture, it appears 
that increased AC6 expression is beneficial as a chronic heart failure treatment (137-140). In 
fact, heart failure mortality is raised by decreases in activity and/or expression of AC6 (141-
143). Thus, AC5 and AC6 selectivity is important when considering cAMP signaling changes 
in the development of heart failure risk. 
 
1.7 Pharmacological Control of AC/cAMP 
Many drugs control cAMP signaling for therapeutic benefit. Development of congestive 
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heart failure involves changes in the expression of multiple proteins associated with the 
AC/cAMP signaling pathway (144-146). Consistent with this, beta-blockers target β-adrenergic 
receptors, decrease cAMP levels, and are used as treatments for various heart conditions, such 
as metaprolol for hypertension and heart failure. Similarly, the µ-opioid receptor ligand 
morphine decreases cAMP, resulting in decreased pain sensation. In addition to these specific 
examples, there are various dopamine receptor ligands utilized as therapeutics for 
schizophrenia, Parkinson’s disease, and nausea. However, direct control of cAMP production 
by targeting AC activity has been more difficult. For example, an AC inhibitor must be cell 
permeable. This has limited the kind of molecules that progress past cell-based systems and 
preclinical animal models, particularly since many AC inhibitors used in research have 
phosphate groups. Some AC inhibitor prodrug packages have been attempted as a solution for 
delivering phosphate-containing AC inhibitors rather than developing new ones, but currently 
no such attempts have clinical testing (147, 148). This includes prodrug modifications with 
cleavable bonds for improved cellular delivery (149). 
A classic group of small molecule AC inhibitors is the P-site inhibitors, which bind in 
the AC catalytic cleft at the ATP binding site (the “P-site”). P-site inhibitors typically decrease 
AC activity through uncompetitive inhibition (150, 151). Uncompetitive inhibition by P-site 
inhibitors is due to the stabilization of a product-like transition state, where the inhibitor binds 
with pyrophosphate in the ATP binding site after cAMP product has been released. As a result, 
P-site inhibitors more strongly inhibit stimulated AC (152). Some classic P-site inhibitors occur 
within cells, especially ADP and ATP metabolites (153). More potent ATP-like P-site 
inhibitors can bind without a pyrophosphate molecule, and such AC inhibitors can have a 
greater than 10-fold stronger affinity for AC than single-phosphate analogs; for example, 2’5’-
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dideoxy-3’-ATP has an IC50 of 40 nM while 2’5’-dideoxy-3’-AMP has an IC50 of 460 nM (154, 
155). Another example is the noncompetitive ATP analog 2’,3’-dideoxy-5’-ATP, the most 
potent AC P-site inhibitor, which can bind to rat brain AC with a Ki of 16 nM (156). However, 
classic P-site inhibitors are not typically AC isoform selective. For example, 2’-deoxy-3’-AMP 
is very mildly selective for AC1 over AC2 and AC6, and only under Mn2+-stimulated but not 
Mg2+-stimulated conditions (157). These are minor shifts in affinity that do not provide many 
clues for development of AC inhibitors that are both potent and isoform selective.  
The other predominant class of direct small molecule AC inhibitors is the MANT-
nucleotide inhibitors. The original MANT-nucleotide studied for AC inhibition is MANT-GTP, 
which has a Ki of 53nM for AC in S49 lymphoma cell membranes (158). MANT-GTP binds in 
the ATP-binding site like the noncompetitive P-site inhibitors, but with the nucleotide group 
bound in a reversed orientation (159, 160). MANT-nucleotide based inhibitors, including 
MANT-GTP, show potential for designing AC isoform selective compounds that target the AC 
catalytic site (159, 161). MANT-GTPγS blocked AC5-coupled L-type calcium channel currents 
when introduced inside cardiomyocytes via patch pipette, although a nonspecific AC-
independent change in current was also observed (162). 
Beyond these two main classes of AC inhibitors, there has also been further 
development targeting alternative sites of AC inhibition. One example is the non-competitive 
inhibitors that target the forskolin binding pocket, which typically are analogs of forskolin. The 
current examples of identified AC inhibitors using this approach are BODIPY-Fsk, and 
6A7DA-FS (also known as iso-forskolin), which showed AC stimulations at micromolar 
concentrations in vitro but AC2 specific inhibition at nanomolar concentrations that was Mg2+ 
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dependent (163, 164). Calmidazolium, classically a calmodulin inhibitor, has also been 
characterized as an allosteric, nonselective AC inhibitor with unknown site(s) of action (165). 
Based on these four groups, there have been attempts to develop similarly potent small 
molecule AC modulators, but with isoform selectivity and greater therapeutic potential. One 
such example, NB001, is a patented AC1 selective inhibitor (166, 167). Catalytic site AC 
inhibitors have been able to differentiate between targeting sAC instead of the 9 membrane 
bound AC isoforms (168). Some small molecules derived from P-site inhibitors, such as PMC-
6 appear capable of integrating metal chelating properties at catalytic site binding to produce 
isoform selective inhibition (169). NKH477, a forskolin analog, can function as an AC5 
activator (170). Effects of NKH477 treatment include coronary vasodilation and rescued 
function in the event of acute heart failure (139, 171). 
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1.8: Previous Work with Known and Novel AC Inhibitors 
NKY80 is a P-site type inhibitor with a modified adenine structure, eliminating DNA 
synthesis inhibition as a potential off-target effect (148). An adenine-like motif at the C2 and 
C6 carbons was preserved and accurately predicted to be essential for AC5 inhibition. 
Consistent with this motif, NKY80 was capable of inhibiting AC5 with an IC50 in AC 
membrane assays of 8.3 µM, a 15-fold and 200-fold difference in potency over AC3 and AC2 
respectively (172). Non-competitive mechanism of AC inhibition was also a conserved 
property between classic P-site inhibitors and NKY80. To further characterize the selectivity of 
Figure 3: Chemical Structures of Small Molecule AC Inhibitors. Top row is P-site derived 
AC inhibitors used in the following experiments and/or previous work. Bottom row is 
representatives from the four main classes of small molecule AC inhibitors currently in use (P-
site inhibitors, MANT-nucleotides, forskolin analogs, and calmidazolium). 
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NKY80 against all nine isoforms of AC, we utilized a membrane assay, as NKY80 cannot 
function in cell-based assays of AC activity (173). We observed that NKY80 inhibition of the 
closely related AC5 and AC6 isoforms was more potent than inhibition of AC 1/2/3/4/7/8/9, 
and that the most-inhibited AC5/6 isoforms were the only clear isoform group that could be 
identified from these inhibition curves (174). Furthermore, virtual docking with AutoDock was 
used to predict how NKY80 bound within the AC catalytic pocket. Based on virtual docking 
results, NKY80 binds in the AC catalytic pocket as a P-site inhibitor in the ATP binding site 
(174). Thus, the presumed AC5 inhibitor NKY80 was an AC5/6 selective P-site inhibitor. 
Due to the selectivity issues for P-site inhibitor derived compounds such as NKY80, we 
also wanted to assess the viability of non-adenine like small molecules inhibiting AC activity at 
the ATP binding site. This was considered as an alternative to identifying new sites for isoform 
selective AC inhibition, such as the forskolin binding pocket, or repurposing inhibitors such as 
calmidazolium with unknown AC interaction sites. By screening a library of 35,000 drug-like 
small molecules from ChemBridge using a ligand-flexible virtual docking approach at the 
ATP-binding site, we identified a trio of small molecules that were novel AC inhibitors. In AC 
membrane assays, these non-optimized molecules could inhibit AC5 at 1mM, and showed 
limited 2-3 fold differences in selectivity at 100µM between AC1/2/5/6 (1, 174). Although 
these identified inhibitor candidates did not display the desired nanomolar levels of potency or 
the therapeutically required AC isoform selectivity, they established proof of concept that this 
combination of high throughput structure-based virtual screening with medium throughput in 
vitro characterization could identify novel AC inhibitors. Such candidates can be further 
optimized to create more potent and selective AC inhibitors. 
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1.9 Significance of Proposed Research 
AC1-9 all produce cAMP, are expressed in multiple tissues, and have many associated 
functions. However, all isoforms share a similar topology. Thus, AC isoform differences in 
physiological function are likely due to different regulatory profiles. A physiological example 
of AC isoform selective regulation is by Gβγ, since it can conditionally enhance stimulation of 
ACs 2, 4, 5, 6, and 7, but inhibit ACs 1, 3, and 8. Pharmacological work to identify isoform 
specific AC inhibitors with therapeutic potential has also provided examples of selectivity in 
regulation despite the shared overall AC structure, including in the catalytic C1/C2 pocket. 
Isoform specific AC functions could be explained by subtle differences in isoform 
specific regulation, despite such regulatory details being incompletely characterized. I 
hypothesize that necessity and sufficiency of AC isoforms in physiological functions is due to 
regulatory differences, and can be characterized through either direct regulatory modulation 
or via isoform specific pharmacological modulation. Thus, I explored isoform specificity of 
AC5/6 from two approaches. One was to more completely characterize the small molecule AC 
inhibitors, primarily those allegedly able to select between AC5 and AC6. The other approach 
was to look at an isoform specific regulator of AC activity, the heterotrimeric Gβγ protein, to 
more closely examine Gβγ regulation of AC5 regarding an NT binding site that AC6 did not 
share, even though both isoforms are conditionally stimulated by Gβγ. 
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Chapter 2 
Materials and Methods 
 
2.1 Plasmids and Viruses 
Rat AC1-4, human AC5, human AC6, and rat AC7 baculoviruses were described 
previously (14, 18, 23, 34, 175). Eukaryotic expression vectors for rat AC2, rat AC8 and 
human AC9 in pcDNA3.1 were described previously (102, 176). Hexa-histidine tagged Gαs 
was purified from E. coli and activated with GTPγS (23). Baculoviruses for biotinylated Gβ1 
(both wildtype and mutants), Gγ2, and Gαi were used to express b-Gβ1γ2 variants as described 
(177, 178).  
Flag-tagged AC5 pcDNA was a generous gift from Dr. Michael Kapiloff (University of Miami, 
FL) and has been used previously (95). YN-Gβ1 was a generous gift from Catherine Berlot 
(Weis Center for Research, Danville, PA) and consists of Gβ1 fused to the first 157 aa of YFP 
(YN). The YN-Gβ1-W99A pcDNA plasmid was generated by PCR mutagenesis. NT23-27 was 
generated by mutagenesis of the Gβ1 aa 23-27 sequence KACAD to ANCAA and cloned into 
the YN-Gβ1 or YN-Gβ1-W99A pcDNA template to produce either YN-Gβ1-NT23-27 or YN-
Gβ1-NT23-27/W99A double mutant pcDNA plasmid. 
 
2.2 Antibodies 
Antibodies used were rabbit anti-Gβ (Santa Cruz), mouse anti-GST (Santa Cruz), rabbit 
anti-H6 (Bethyl), rabbit anti-GFP (Cell Signaling), and anti-Flag (Sigma). 
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2.3 Small Molecules 
Forskolin and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich.  The AC 
inhibitors SQ22,536 (Enzo Biosciences), Ara-A under the trade name Vidarabine (Tokyo 
Chemical Industry), and NB001 (Sigma-Aldrich) were purchased from the indicated vendor. 
All small molecules were purchased in solid form and suspended in DMSO. In membrane AC 
assays (see below), the final concentration of DMSO in adenylyl cyclase assays was always 
less than 5%. 
 
2.4 Virtual Ligand Docking 
Global and site-directed docking of selected AC inhibitor ligands was performed using 
AutoDock 4.2 (Scripps, La Jolla, CA).  Here, known AC5 inhibitors SQ22,536 and Ara-A were 
docked to either the entire surface of AC structures or just to the ATP binding site. The 
structures of AC used were PDB ID’s 1CJT and 1TL7, which are crystallized chimeras of the 
AC5 C1 domain and AC2 C2 domain. In the former “blind docking” procedure (179), we used 
a cubic grid of size 60 Å (with spacing of 0.375 Å) centered on the C1/C2 domain. For site 
directed docking to the ATP-bound site, docking was restricted to a cubic grid with sides 20 Å 
in length, in order to encompass the ATP binding site as the docking region. This box was 
centered on the crystallized P-site inhibitor (1CJT) or MANT-GTP inhibitor (1TL7). Prior to 
their use in AutoDock docking runs, ligands were preprocessed with AutoDock Tools including 
assignment of Gasteiger atomic charges and torsions (180, 181). 
AutoDock 4.2 was then used to dock the ligands onto a grid large enough to encompass 
the entire surface of the AC catalytic site from crystal structure 1CJT. An LGA hybrid with 256 
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runs was used, with maximum generation of 10,000, and population size of 150. A cutoff of 2 
Å RMSD was used for clustering. Predicted poses were analyzed in terms of their energetic 
binding potential. Hydrogen bonds were defined by a donor-acceptor distance cutoff of 3.5 Å 
and a donor-hydrogen-acceptor angle between 150° and 180°. Van der Waals contacts were 
defined by a carbon-carbon distance cutoff of 5.0 Å. 
A combination of the ICM-browser (Molsoft LLC) and VMD 1.9 (Theoretical and 
Computational Biophysics Group at the University of Illinois at Urbana-Champaign) (182), 
both freely available, were used for visual analysis ofl docking results and image rendering. 
 
2.5 AC Sequence Alignment 
Alignment of two or more AC sequences using BLAST (http://blast.ncbi.nlm.nih.gov/) 
was utilized to compare primary sequence for the domains of various AC isoforms. The 
primary sequences of the C1/C2 domains used in a crystallized AC structure (PDB ID 1CJT) 
were aligned with the corresponding C1/C2 sequences of human AC1-9. Various regions of 
AC5 C1 and C2 were also aligned with AC2 C1 and C2 sequences containing identified Gβγ 
interaction and/or activation sites. 
 
2.6 C1/C2 Domain and G Protein Purifications 
Proteins 5C1(670)H6, H65C2, and GαsH6, were expressed in Escherichia coli and 
purified as described previously (32, 183, 184). GST-tagged proteins were expressed in 
Escherichia coli and purified using glutathione agarose resin as described previously (99). 
Non-tagged or biotin-tagged Gβ1γ2 was coexpressed with GαiH6 in clonal isolates of 
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Spodoptera frugiperda (Sf9) insect cells and purified on nickel-NTA columns, followed by 
either overnight dialysis or ion exchange as described previously (33). 
 
2.7 Sf9 AC Expression 
  Clonal isolates of Sf9 cells were maintained in cell suspension flasks with SF-900 II 
SFM media at 27°C. Baculoviruses encoding AC isoforms or G protein subunits were 
amplified for 5-7 days using 500µl of storage virus stock with 50ml of Sf9 cells in log phase in 
SF-900 II SFM media with 50 μg/ml gentamicin at a concentration of 1.5-2 × 106 cells/ml to 
produce a baculovirus working stock with a minimum titer of 1 × 107 pfu/ml. 25ml of the 
appropriate AC isoform baculovirus was used to infect 1 liter of Sf9 cells at a concentration of 
1.5-2 X 106 cells/ml. After 48 hours of infection, Sf9 cells were harvested by centrifugation at 
1000 g for 10 minutes at 4°C. 
 
2.8 Sf9 Membrane Preparation 
Harvested Sf9 cells were suspended in ice-cold lysis buffer consisting of 20 mM 
HEPES (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1 mM EGTA, 2 mM DTT, and protease 
inhibitors phenylmethylsulfonyl fluoride, tosyl phenylalanyl chloromethyl ketone, leupeptin, 
lima bean trypsin inhibitor, and aprotinin. Cells were lysed by nitrogen cavitation at 500 psi for 
30 minutes at 4°C. Cell lysates were centrifuged at 750g for 10 minutes to remove intact cells 
and nuclei. The supernatants were centrifuged at 100,000g for 30 minutes, and the resulting 
pellets were resuspended and washed in buffer consisting of 20 mM HEPES (pH 8.0), 2 mM 
DTT, 200 mM sucrose, and protease inhibitors as previously described. Membranes were 
homogenized with a Dounce homogenizer and centrifuged again at 100,000g for 30 minutes. 
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Resuspended Sf9 membrane pellets had concentration determined by Bradford assay, with 
membranes then immediately frozen in liquid nitrogen and stored at -80°C in one-use aliquots 
for future adenylyl cyclase activity assays (see below). 
 
2.9 HEK293 and COS-7 Cell Transfections and Membrane Preparations 
HEK293 or COS-7 cells were maintained in Dulbecco’s Modified Eagle Medium 
(DMEM) with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C with 5% CO2. 
All volumes and amounts are for transfection in 10cm plates for membrane preparations. 
HEK293 (3 × 106 cells) and COS-7 cells (2 × 106 cells) were seeded 24 hours prior to 
transfection in 10cm dish. Medium was replaced the next day with fresh DMEM (no 
penicillin/streptomycin) and cells were transfected with the appropriate plasmids (10 µg DNA 
total per 10cm plate) using Lipofectamine 2000 in a 1:3 µg DNA: µg lipofectamine ratio. Cells 
were incubated at 37°C for 4-6 hours, the media was replaced, and membranes prepared 
approximately 42 hours (COS-7 cells) or 42-48 hours (HEK293 cells) after transfection.  
Following transfections, cells were rinsed and harvested in cold PBS then pelleted by 
centrifugation at 3000g, 4°C for 5 min. Cell pellets were aspirated and resuspended in 20 mM 
HEPES, 1 mM EDTA, 2 mM MgCl2, 1 mM DTT, 250 mM sucrose, and protease inhibitors. 
Cells were incubated on ice for 10-30 min, subjected to dounce homogenization, and 
centrifuged at 1800g for 5 min at 4°C to pellet nuclei. The supernatants were centrifuged at 
60,000g, 4°C for 20 min. The resulting membrane pellet was resuspended in 20 mM HEPES, 1 
mM EDTA, 2 mM MgCl2, 1 mM DTT, 250 mM sucrose, and protease inhibitors. 
HEK293/COS-7 membrane concentrations were determined by Bradford assay. Membranes 
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were immediately used in adenylyl cyclase activity assays or frozen in liquid nitrogen and 
stored at -80°C in one-use aliquots for future assays. 
 
2.10 Adenylyl Cyclase Membrane Activity Assays 
As performed and described previously (185, 186), Sf9, COS-7, or HEK membrane 
preparations (see above) were incubated for 10 minutes at 30°C with an AC mix containing [α-
32P]ATP, 10 mM MgCl2, and appropriate activators, including forskolin or GTPγS-Gαs with or 
without the indicated concentrations of Gβγ. When applicable, inhibitors in DMSO (1µl) were 
added on ice before the addition of activators. The activators used were 50µM forskolin for Sf9 
membranes of AC1-7, 100µM calcium and 300µM calmodulin for HEK membranes of AC8, 
50nM Gαs for membranes expressing AC1-8 or 300nM Gαs for HEK membranes of AC9. 
Final volume of these reactions was 50 µl. Reactions were stopped with 850 µl of a solution of 
2.5% SDS, 50 mM ATP, and 1.75 mM cAMP. Nucleotides in each reaction sample were then 
separated by sequential column chromatography on Dowex and Alumina resins to isolate 
[32P]cAMP product, using [3H]cAMP to monitor column recovery rates. Separated samples 
were collected in scintillation vials with scintillation fluid, and production of cAMP was 
measured by scintillation counting using a dual dpm program to count [3H]cAMP and 
[32P]cAMP isolated from each sample. 
 
2.11 Intact cAMP Accumulation Assays 
HEK293 cells were transfected with either AC1 or a pcDNA vector control in poly-
lysine coated 6-well plates. 48 hours post transfection, cells were labeled with [3H]adenine for 
3-4 hours, washed, and incubated with 1 mM 1-methyl-3-isobutylxanthine (IBMX) and either 
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NB001 or a DMSO vehicle control at 37°C for 10 min. Forskolin (10 µM) and ionomycin (10 
µM) were incubated for an additional 30 min. Reactions were stopped upon addition of ice-cold 
5% trichloroacetic acid (TCA), 1 mM ATP, and 100 µM cAMP. Nucleotides were then 
separated by column chromatography to isolate [3H]cAMP product, using [32P]cAMP to 
monitor column recovery rates. [3H]cAMP and [32P]cAMP separation and counting were 
performed as described above for AC membrane activity assays. 
 
2.12 Pull-Down Binding Assays 
GST or GST-tagged AC NT (full-length or truncations) were incubated with purified 
Gβγ subunits in 50 μl of binding buffer (20 mM HEPES, pH 8.0, 1 mM EDTA, 5 mM MgCl2, 2 
mM DTT, 100 mM NaCl, 0.1% C12E9). The proteins were incubated for 30 min at 4°C 
followed by addition of 100 μl of 20% glutathione-agarose beads. After rotating for 2 hours at 
4°C, the resin was washed three times with wash buffer (20 mM HEPES, pH 8.0, 1 mM EDTA, 
5 mM MgCl2, 2 mM DTT, 100 mM NaCl, 0.05% C12E9). Bound proteins were eluted with 15 
mM glutathione and analyzed by SDS-PAGE and Western blotting. 
For biotin-tagged protein pulldowns, purified biotin-tagged Gβγ was incubated with 
His-tagged 5C1(670)H6 in 50µl of binding buffer for 30 min at 4°C. After incubation, 100 μl of 
20% streptavidin-agarose beads was added to the samples, rotated for 2 hours at 4°C, and the 
resin was subsequently washed three times with wash buffer. Bound proteins were eluted from 
the streptavidin-agarose by direct addition of 1X Laemmli buffer and analyzed by SDS-PAGE 
and Western blotting. 
 
2.13 Flag-AC5 Immunoprecipitation  
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Human Flag-tagged AC5 was transfected in HEK293 cells (10 cm dish/IP). After 40 
hours, HEK293 cells were rinsed with phosphate-buffered saline, resuspended in lysis buffer 
(50 mM HEPES, pH 8.0, 1 mM EDTA, 1 mM MgCl2, 1 mM DTT, 150 mM NaCl, 0.5% C12E9, 
and protease inhibitors), and homogenized using a 23-gauge syringe. Cellular debris was 
removed by centrifugation, and 30 μl of anti-Flag agarose was added. Samples were rotated at 
4°C for 2 h, and then washed three times with lysis buffer that contained only 0.05% C12E9. 
Proteins were eluted from anti-Flag resin with SDS-PAGE sample buffer, and analyzed by 
SDS-PAGE and Western blotting. 
 
2.14 Gβγ Binding Overlays 
BSA controls, His-tagged AC5/6 C1 or C2 domains were run on SDS-PAGE gels and 
transferred to polyvinyldifluoride membranes. After blocking with 5% milk for 1 hour, PVDF 
membranes were incubated overnight with 10 µg purified Gβγ in 3 ml of overlay wash buffer 
(Tris-buffered saline pH 7.4, 0.1% Tween-20, and 1mM DTT) overnight at 4°C. Bound Gβγ 
was detected by Western blotting. 
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Chapter 3 
Characterized Isoform Selectivity of Adenylyl 
Cyclase Inhibitors 
 
Results figures in this chapter have been reprinted with permission from the following 
publications (text describing results partially reprinted with permission from Brand et al. only): 
Brand CS, Hocker HJ, Gorfe AA, Cavasotto CN, Dessauer CW. Isoform Selectivity of 
Adenylyl Cyclase Inhibitors: Characterization of Known and Novel Compounds. J Pharmacol 
Exp Ther. November 2013, 347:265-275. 
Conley JM, Brand CS, Bogard AS, Pratt EP, Xu R, Hockerman GH, Ostrom RS, Dessauer 
CW, Watts VJ. Development of a high-throughput screening paradigm for the discovery of 
small molecule modulators of adenylyl cyclase: Identification of an adenylyl cyclase 2 
inhibitor. J Pharmacol Exp Ther. November 2013, 347:276-287. 
 
3.1 Rationale 
AC inhibitors, through decreasing cAMP production, have therapeutic potential. This is 
supported by the use of Gαs-coupled GPCR antagonists, such as beta blockers for treating heart 
diseases, or Gαi-coupled GPCR agonists, such as opioids for treating pain. However, in order 
for AC inhibitors to have much therapeutic potential, they should be selective for an AC 
isoform or subset of isoforms. Otherwise, due to the many cAMP-associated physiological 
functions, off-target effects would be probable. Similar issues are seen for the above GPCR 
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ligands that target upstream of AC. Previously developed AC inhibitors have been shown to be 
selective while only comparing a subset of AC isoforms; the incomplete characterization of 
such an approach has already been observed for NKY80. 
There are other small molecule inhibitors allegedly specific for AC5 that are related to 
NKY80; namely, SQ22,536 and Ara-A. These small molecules have been proposed to be AC5 
selective compared to AC2 and AC3, three relatively dissimilar isoforms with regards to 
overall regulatory patterns (157, 172, 173). Additionally, SQ22,536 and Ara-A have worked for 
intact cell AC inhibition, an issue for many selective AC inhibitors (187). However, neither 
compound was tested against all 9 transmembrane AC isoforms. Since these inhibitors are also 
derived from P-site inhibitors, they also have similar adenine structures which bring up the 
issues of potential off-target effects. These potential issues are not restricted to alleged AC5 
inhibitors; the allegedly AC1-specific inhibitor NB001 has a chemical structure extremely 
similar to ATP. Thus, we proposed to more vigorously characterize the isoform selectivity of 
small molecule AC inhibitors such as SQ22,536, Ara-A, and NB001. 
 
3.2 “AC5” Inhibitors Are Actually AC5/6 Selective Inhibitors 
 SQ22,536 and Ara-A are three adenine-like inhibitors that are reportedly selective for 
AC5 (157, 172, 173) (the chemical structure of these ligands is shown in Figures 4A and 5A 
while the 3D structure of the ligand-AC complexes obtained from docking is shown in Figures 
4B and 5B). However, these inhibitors have never been tested against all nine membrane-bound 
AC isoforms. Using an in vitro AC activity assay with Sf9 or HEK293 membranes expressing a 
given AC isoform, we tested these inhibitors for their potency against each transmembrane AC.  
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SQ22,536 was the first P-site inhibitor analog without phosphates developed, and is 
essentially a dideoxyadenosine analog (Figure 4A). It has been previously shown to be 
selective for AC5 over AC 2 or 3 (157, 172). In addition to confirming these results, we show 
that SQ22,536 has high potency for AC 5 and 6 with 10-15 fold selectivity over the next closest 
isoform, AC1. Potency and efficacy for AC 2, 3, 4, 7, 8, and 9 are further reduced, with less 
than 50% inhibition of AC8 and 9 at 1 mM. Although inhibition of AC 8 and 9 appears to level 
off slightly, this is likely only due to our inability to further increase inhibitor concentrations 
and reach complete saturation. Importantly, inhibition by SQ22,536 is not significantly 
different for AC5 and AC6 (Figure 4C and Table 1).  
Ara-A, also known as vidarabine, is an adenosine analog (Figure 5A) that is used 
clinically as an antiviral, with a mechanism that is unrelated to inhibition of AC/cAMP 
signaling (188). Ara-A was shown previously to be selective for AC5 over AC 2 and 3 when 
expressed in Sf9 membranes, and has been suggested to inhibit AC5 more potently than AC6 in 
cardiomyocytes (189). We show that, similar to SQ22,536, Ara-A most potently inhibits AC 5 
and 6 (Figure 5C and Table 1). Additionally, for any given concentration of Ara-A, we observe 
less than a 2-3 fold difference in the inhibition of AC5 versus AC6. Therefore SQ22,536 and 
Ara-A, in addition to NKY80, are actually AC5/6 selective inhibitors. 
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Figure 3: AC Inhibition Profile of SQ22,536. A, Chemical structure of SQ22,536. B, Virtual 
docking of SQ22,536 to a P-site inhibitor-bound conformation of AC (PDB 1CJT). SQ 22,536 
is shown with cyan carbons; the crystallized position of 2’,3’-dd-ATP ligand shown with grey 
carbons for reference. C1 domain is yellow; C2 domain is silver. C, Inhibition profile of 
SQ22,536 for all 9 AC isoforms. Inhibition curves for each AC is shown as a calculated fit to 
the means of each concentration (indicated by symbols and grouped with colors by AC family; 
n=3, performed in duplicate; error bars removed for clarity). Membranes from Sf9 cells 
expressing AC 1-7 were stimulated by 50 µM forskolin. Membranes from HEK293 cells 
expressing AC 8 and 9 were stimulated by 300 µM calmodulin, and 300 nM Gαs, respectively. 
Reproduced from Brand CS, Hocker HJ, Gorfe AA, Cavasotto CN, Dessauer CW. Isoform 
Selectivity of Adenylyl Cyclase Inhibitors: Characterization of Known and Novel Compounds. 
J Pharmacol Exp Ther. November 2013, 347:265-275 (1). 
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Figure 4: Ara-A Does Not Discriminate Between AC5 and AC6. A, Chemical structure of 
Ara-A. B, Virtual docking of Ara-A to the 2’3’-dd-ATP bound conformation of AC as 
described for Figure 3B. C, Complete AC isoform inhibition profile of Ara-A. Inhibition 
curves for each AC isoform shown as fit to means of AC activity assays (n=3). Membranes and 
stimulation conditions were as described in Figure 3C (n=3, performed in duplicate). 
Reproduced from Brand CS, Hocker HJ, Gorfe AA, Cavasotto CN, Dessauer CW. Isoform 
Selectivity of Adenylyl Cyclase Inhibitors: Characterization of Known and Novel Compounds. 
J Pharmacol Exp Ther. November 2013, 347:265-275 (1). 
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Table 2: Pharmacological Profile for Inhibition of Adenylyl Cyclase Isoforms 
Inhibitor 
pIC50 +/- S. E. (IC50 in µM) 
AC1 AC2 AC3 AC4 AC5 AC6 AC7 AC8 AC9 
SQ22,536 
4.27 +/- 
0.09**  
(54) 
3.71 +/- 
0.23** 
(210) 
3.96 +/- 
0.09** 
(110) 
3.55 +/- 
0.04** 
(280) 
5.46 +/- 
0.08 
(3.5) 
5.25 +/- 
0.14 
(5.8) 
3.38 +/- 
0.16** 
(440) 
#,  
(>1000) 
#,  
(>1000) 
Ara-A 
4.31 +/- 
0.09**  
(50) 
3.61 +/- 
0.05** 
(250) 
4.07 +/- 
0.01** 
(85) 
4.03 +/- 
0.22** 
(100) 
5.67 +/- 
0.05 
(2.2) 
5.34 +/- 
0.13* 
(4.7) 
3.64 +/- 
0.07** 
(230) 
#,  
(>1000) 
#,  
(>1000) 
Experiments performed as described in Fig 1C-3C. Values are reported as pIC50 +/- S.E., where 
pIC50 is calculated as -log(IC50). n=3, each performed in duplicate. Statistics (t-test) were 
performed on pIC50 of the indicated isoform versus that of AC5. *p < 0.05, **p < 0.001, # Did 
not reach 50% activity at 1 mM inhibitor; ^ Did not reach 50% inhibition in one experiment. 
Table adapted from Brand CS, Hocker HJ, Gorfe AA, Cavasotto CN, Dessauer CW. Isoform 
Selectivity of Adenylyl Cyclase Inhibitors: Characterization of Known and Novel Compounds. 
J Pharmacol Exp Ther. November 2013, 347:265-275 (1). 
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3.3 Mutation of Serine 942 in AC2 Forskolin Pocket Does Not Alter Inhibition 
Global docking of SQ22,536 and Ara-A predicted that these inhibitors frequently 
(~70% and ~50%, respectively, see Table 2) target the ATP binding site of the AC C1/C2 
domains (1CJT).  Similar docking to the MANT-GTP bound conformation of AC (1TL7) was 
less predictive, suggesting that these molecules bind to a similar AC conformation as their 
classical P-site predecessors. 
The catalytic and forskolin sites are pseudosymmetrically related. Although forskolin is 
an AC activator, inhibitors that target the forskolin binding site have been identified (163, 164). 
Since our virtual screening focused only on the ATP site, we wanted to rule out that SQ22,536 
and the other molecules that inhibited AC activity do not exert their actions through 
interactions with the forskolin pocket. To this end, we mutated residues within the forskolin-
binding pocket. From the crystal structure of AC, Ser942 in the C2 domain of AC2 interacts 
with forskolin but does not contribute to C1-C2 interaction (12). Since substitution of this 
residue by proline was predicted to prevent hydrogen bonding to a nearby water molecule and 
distort the forskolin binding pocket, we mutated Ser942 to proline in AC2 and prepared 
membranes from COS-7 cells expressing the wild-type and mutant proteins. Ser942P activity 
had decreased sensitivity to stimulation by forskolin compared to wild-type AC2, while basal 
activity and stimulation by Gαs were not significantly altered (Figure 6A, 5B). Synergistic AC2 
activation by both forskolin and Gαs was also impaired in the Ser942P mutant. However, the 
mutation had no effect on inhibition of Gαs-stimulated AC2 by SQ22,536 (Figure 6C), 
supporting an interaction of these inhibitors with the ATP binding site. Forskolin pocket 
mutation also had no effect on inhibition of Gαs-stimulated AC2 by CB-7833407, a novel AC 
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inhibitor without adenosine-like structure identified previously in a structure-based virtual 
screen of the ATP binding site of AC. 
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Figure 5: Mutation of AC2 Forskolin 
Binding Pocket Does Not Impair Inhibition 
by SQ22,536. A, Basal activity of COS-7 
membranes expressing AC2 wildtype, AC2 
S942P mutant, or a pcDNA control was 
measured. B, COS-7 membranes expressing 
AC2 wildtype, AC2 S942P mutant, or a 
pcDNA control were incubated with 10 µM 
forskolin and/or 50 nM activated Gαs and AC2 
activity was measured. C, COS-7 membranes 
expressing AC2 wild-type, AC2 S942P mutant, 
or a pcDNA control were preincubated in the 
absence or presence of the indicated inhibitor 
(100 µM SQ22,536 or 500 µM CB-7833407) 
and then stimulated with 50 nM Gαs. Statistics 
(paired t-test) for inhibition of AC2 WT/S942P 
by the indicated AC inhibitor, *p < 0.05, **p < 
0.01, and for differences between inhibition of 
AC2 WT vs. S942P, n.s. - not significant. 
Reproduced from Brand CS, Hocker HJ, Gorfe 
AA, Cavasotto CN, Dessauer CW. Isoform 
Selectivity of Adenylyl Cyclase Inhibitors: 
Characterization of Known and Novel 
Compounds. J Pharmacol Exp Ther. November 
2013, 347:265-275 (1). 
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Table 3: Global Docking of Small Molecule Inhibitors to AC Catalytic Domains 
Inhibitor 
% of Docking Hits at Indicated Site (% of Total 
Docks) 
AC Without Bound 
Forskolin 
AC With Bound 
Forskolin 
ATP 
Binding 
Site 
Fsk 
Binding 
Site 
 ATP 
Binding 
Site 
Fsk 
Binding 
Site 
SQ22,536 69.9% 0.8%  68.7% 0.8% 
Ara-A 47.7% 10.9%  42.6% 0.8% 
Global docking with AutoDock performed as described in Materials and Methods using the 
2’3’ddATP-bound conformation of AC (1CJT). Percentages are based upon 256 independent 
docking runs. Table adapted from Brand CS, Hocker HJ, Gorfe AA, Cavasotto CN, Dessauer 
CW. Isoform Selectivity of Adenylyl Cyclase Inhibitors: Characterization of Known and Novel 
Compounds. J Pharmacol Exp Ther. November 2013, 347:265-275 (1). 
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3.4 “AC1 Inhibitor” NB001 Does Not Directly Inhibit AC1 Activity 
 To gain further insight into the selectivity of different AC inhibitors, we also examined 
NB001, which is reported to be an AC1 selective ligand with therapeutic potential as an 
analgesic (US patent #8,124,599). In HEK cells stably expressing AC1, NB001 inhibited AC 
activity when stimulated with forskolin and the calcium ionophore calimycin (166). We also 
observed NB001 inhibition of cAMP accumulation in HEK cells transiently expressing AC1 
when stimulated with ionomycin and forskolin (Figure 7B). However, this experiment 
performed both by us and Wang et al.. detects cAMP accumulation within the cell and does not 
necessarily reflect solely AC1 activity. We were unable to inhibit AC1 activity in vitro by 
NB001 when assayed in membranes prepared from HEK293 cells expressing AC1, as used in 
the cAMP accumulation assays (Figure 7C). This lack of direct action of NB001 on AC1 was 
irrespective of activation conditions, including stimulation by forskolin, calmodulin, or the 
combination of forskolin and calmodulin to mimic the effects of forskolin and ionomycin in 
intact cells. This suggests that although NB001 can reduce cAMP accumulation in cells in an 
AC1-dependent manner, the ligand is not acting through direct inhibition of AC1 activity. 
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Figure 6: NB001 Decreases AC1-dependent 
cAMP Accumulation but Does Not Directly 
Inhibit AC1. A, Chemical structure of NB001. 
B, HEK293 cells expressing AC1 or pcDNA 
control were incubated with NB001 (10 or 100 
µM) or vehicle prior to stimulation with 10 µM 
forskolin and 10 µM ionomycin. Statistics (t-
test) for NB001 inhibition, *p < 0.05. C, NB001 
(100 µM) or vehicle control were incubated 
with membranes from HEK293 cells expressing 
AC1 and stimulated as indicated. Reproduced 
from Brand CS, Hocker HJ, Gorfe AA, 
Cavasotto CN, Dessauer CW. Isoform 
Selectivity of Adenylyl Cyclase Inhibitors: 
Characterization of Known and Novel 
Compounds. J Pharmacol Exp Ther. November 
2013, 347:265-275 (1). 
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3.5 Small Molecules from Cell-Based Screen Show Direct AC2 Inhibition 
Given the nonspecific effects observed in this work and cited literature, it is not 
surprising that various groups are looking for alternative screening methods to identify isoform 
specific small molecule AC inhibitors. One such target is AC2, due to its inhibition producing 
effects on skeletal muscle development (190-192), both neuroendocrine and colorectal cancer 
types (193-195), and IL-6 responses in airway smooth muscle (196-198). As such, Conley et al. 
identified novel AC2 inhibitors through a cell-based screen for small molecules from NIH 
clinical libraries that blocked AC2-specific stimulation of cAMP accumulation by treatment 
with PMA. This method produced two promising AC2 inhibitor candidates, tranilast and SKF-
83566 (2). SKF-83566 is also a D1 dopamine receptor antagonist, but at thousand-fold higher 
concentrations than those that directly inhibit AC2 activity (199). 
However, we had also shown via NB001 that AC inhibitors which test well in cell-
based screens may not directly inhibit AC activity. As such, in addition to their work 
identifying these compounds through in-cell screens, we tested their AC2 inhibitor candidates 
in vitro in assays using Sf9 membranes. Both tranilast and SKF-83566 directly inhibit AC2 
activity, and continue to do so in an isoform-specific manner (Figure 8A). In comparison to the 
AC5/6 inhibitor NKY80, the range of difference in AC2 vs. AC5 inhibition at a single 
concentration was more pronounced for both SKF-83566 and tranilast. This differentiates these 
novel candidates from BODIPY-forskolin, a potent AC2 inhibitor yet one that lacks isoform 
selectivity (163, 164, 200). Thus, our results validated that their cell-based PMA stimulation 
assay identified novel isoform selective AC inhibitors that act directly on AC activity. 
In addition, there was some question as to the mechanism of SKF-83566 inhibition of 
AC2. The reason for this was that SKF-83566 was the most promising candidate pulled out of 
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their PMA-stimulation based inhibitor screen. We tested the inhibition of AC2 by SKF-83566 
at set concentrations of 75 or 200 µM or control, and increasing concentrations of ATP. When 
plotted, our results showed a stable Km value but variable Vmax values, indicating that SKF-
83566 candidate was a noncompetitive AC2 inhibitor (Figure 8C). Notably, classic P-site 
inhibitors as well as SQ22,536, Ara-A, and NKY80 are also noncompetitive inhibitors. 
Therefore, like our previously mentioned structure-based virtual screen hits, it is possible that 
SKF-83566 is also a small molecule catalytic P-site inhibitor lacking adenine or ATP-like 
chemical structure. 
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Figure 7: Inhibition of AC Activity in vitro 
by Novel AC2 Inhibitors. (A) The effects of 
100 µM NKY80, SKF-83566, and tranilast on 
forskolin-stimulated (30 µM) AC activity 
were measured in membranes of Sf9 cells 
expressing AC1, AC2, or AC5. **P < 0.01 (t 
test compared with vehicle condition). (B) 
Chemical structures of NKY80, SKF-83566, 
and tranilast. Chemical structures were drawn 
by JM Conley. (C) Double-reciprocal plot of 
AC activity from Sf9 membranes expressing 
AC2 (5 µg) in the presence of 100 nM Gαs 
and in the absence or presence of SKF-83566 
(75 µM or 200 µM) and the indicated 
concentrations of ATP. The data suggest that 
SKF-83566 noncompetitively inhibited AC2 
activity with respect to ATP. Reproduced 
from Conley JM, Brand CS, Bogard AS, 
Pratt EP, Xu R, Hockerman GH, Ostrom RS, 
Dessauer CW, Watts VJ. Development of a 
high-throughput screening paradigm for the 
discovery of small molecule modulators of 
adenylyl cyclase: Identification of an adenylyl 
cyclase 2 inhibitor. J Pharmacol Exp Ther. 
November 2013, 347:276-287 (2). 
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3.6 Summary 
We have shown that allegedly AC5-selective inhibitors SQ22,536 and Ara-A can inhibit 
both AC5 and AC6. This has implications for the therapeutic repurposing of Ara-A; the 
inhibitor blocks both AC5/6 activity, yet was proposed to decrease AC5 activity in 
cardiomyocyte models of heart failure where AC6 inhibition has been suggested to not be 
beneficial, or even detrimental. We identified the site of action as the ATP-binding site in the 
catalytic C1/C2 domains of cyclase, suggesting a P-site inhibitor method of inhibition. We also 
showed that the small molecule inhibitor NB001 does not inhibit AC1 directly, despite 
decreasing AC1-dependent cAMP accumulation within cells. Lastly, we have characterized 
novel AC2 inhibitors that were identified by chemical screening of clinical compound libraries 
and validated their direct effects on AC2 inhibition. Overall, the potential flaws from 
incomplete characterization of selectivity in AC inhibitors have been highlighted, and a cell-
based AC inhibitor screening method has been validated in part through such characterization. 
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Chapter 4 
Adenylyl Cyclase Isoform Specificity of NT 
Interactions and Regulation by Gβγ 
 
4.1 Rationale 
The heterotrimeric Gβγ protein subunit has isoform specific regulatory effects on AC. 
Gβγ can enhance the activation of Gαs- or forskolin-stimulated AC 2, 4, 5, 6, and 7 (18-21, 35). 
In addition, Gβγ can also inhibit the activity of AC 1, 3, and 8 (18, 36, 37). Both Gαs and Gβγ 
subunits are needed to observe a full stimulatory AC6 response to the Gs-coupled receptor 
agonist isoproterenol (93). This suggests that Gβγ generated from activation of Gαs plays a 
regulatory role for enhancement of AC5/6 activity. This differs from the conditional Gβγ 
stimulation of AC2/4/7, where the Gβγ subunit is thought to be provided via activation of Gαi-
coupled GPCRs (19). Differences in Gβγ regulation of AC depending on the GPCR source 
have also been observed via live cell imaging (201). Thus, Gβγ was an avenue for looking at 
differences in AC isoform activity control by the same physiological regulator. 
A binding site for inactive G protein heterotrimer on the NT of AC5 (AC5NT) was 
previously identified, but not required for Gβγ stimulation of AC5 (95). Gβγ binding to 
residues 66-137 of AC5NT is synergistically enhanced in the presence of GDP-Gαs and the 
formation of a heterotrimer (95). Similar scaffolding interactions between AC and 
heterotrimeric G proteins have previously been proposed (202, 203). Other Gβγ effectors, such 
as PLCβ, GIRK channels, and RACK1, are also capable of scaffolding G protein heterotrimers 
45 
 
(67, 204, 205). The binding of Gαs-βγ at the AC5NT is independent from Gβγ stimulation of 
AC5, supporting a model where inactive heterotrimer occupies the NT and a separate event 
results in Gβγ stimulation of AC5. Although both AC5 and the closely related AC6 are 
stimulated by Gβγ, AC6 stimulation by Gβγ requires residues 77-151 of AC6NT (93). 
In the inactive Gα-βγ conformation, regions on the Gα and Gβγ subunits required for 
effector regulation are concealed in a bound heterotrimer. After activation, such regions are 
exposed and can interact with downstream effector proteins such as AC (26). The Gβγ structure 
includes β-sheet WD40 motif repeats, or “blades”, and a “hotspot” area where the turns 
between blades intersect. The “hotspot” on Gβγ is required for interactions with either the alpha 
subunit when inactive, or numerous effectors when active (88, 177, 206). 
We hypothesized that Gβγ requires the “hotspot” to stimulate AC5, but utilizes a 
different surface to interact with AC5NT. A similar scaffold/stimulation mechanism occurs for 
Gβγ and Gαi regulation of GIRK channels (66, 67). We also examined Gβγ hotspot roles in 
stimulation of AC6 and if these properties differed from AC5 regulation by Gβγ, since AC5/6 
are closely related isoforms. 
 
4.2 Gβγ Binds to Various AC Isoform N-Termini 
Gβγ binding to the NT of AC has been observed previously for AC5 and AC6, either 
alone or as a Gs heterotrimer (93, 95). The NT of AC isoforms are varied in their size and 
sequence, and the resepective AC isoforms also vary in the regulatory function of Gβγ (Figure 
9A). To determine if Gβγ binding is a conserved property of all AC NT, GST pulldowns were 
performed using GST-tagged AC-NT and purified Gβγ. As shown in Figure 9B, Gβγ binds to 
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the NT of all AC isoforms tested, including AC1, 2, 3, 5, 6, and 9. Previous studies have also 
identified an interaction between AC8 and Gβ2 (94). 
 
 
 
4.3 Gβγ Scaffolding versus Stimulation of AC5, but Not AC6, Activity are Separable 
Events 
With the AC5NT binding site for Gβγ being a proposed heterotrimeric scaffolding site, 
(95), we predicted that scaffolding at the AC5NT and activation of AC5 were separable events. 
In order to separate these events, we utilized alanine-substituted mutants of the Gβγ “hotspot” 
region required for effector interactions (Figure 10A) (90, 204). Mutations within the Gβγ 
hotspot did not alter binding to AC5NT in GST pulldown assays (Figure 10B). However, when 
Figure 9: Gβγ Binds to Various AC N-Termini. A, Schematic of AC N-Termini grouped by 
similar isoforms. Regulation by Gβγ is indicated, with regulation previously in the literature 
shown indirectly indicated by *, and shown directly otherwise. B, Pulldown of GST-tagged AC 
NT’s with bound Gβγ. The final concentration of GST or GST-tagged NT’s was 2 µM. Inputs 
and elutes from GST pulldowns were analyzed by Western blotting. Figure 8B experiment 
performed by Rachna Sadana. 
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assayed for their ability to increase Gαs-stimulated AC5 activity in vitro, Gβγ hotspot mutants 
were unable to stimulate AC5 (Figure 10C). Histidine 311 serves as a control as it is located 
largely outside the traditional hotspot of Gβγ, located in the junction between blades 6 and 7 
(204). The inability of hotspot mutants to conditionally stimulate AC5 was independent of the 
Gβγ scaffolding site within the AC5NT (aa 66-137) (Figure 10D). This suggests that AC5NT 
binding and stimulation of AC5 by Gβγ are indeed separable events. 
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Figure 10: Gβγ Hotspot Mutants Bind to AC5NT But Are Unable to Stimulate AC5. A, 
Schematic of Gβγ structure, indicating sites of the alanine-substitution hotspot and NT23-27 
mutants used in this paper. Image rendered using Visual Molecular Dynamics (VMD 1.9). B, 
Pulldown of GST or GST-tagged AC5NT (2 µM) incubated with 300 nM wild-type Gβγ (WT) 
or the indicated Gβγ hotspot mutants. Elutes from GST pulldowns were analyzed by Western 
blotting. Experiment performed by Rachna Sadana. C, AC activity assay of Sf9 membranes 
expressing AC5 were stimulated with 50 nM Gαs +/- 300 nM Gβγ. D, AC activity assay with 
Sf9 membranes expressing AC5 with NT residues 66-137 deleted (Δ66-137) were stimulated 
with 50 nM Gαs +/- 300 nM Gβγ. 
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As AC5 and AC6 are closely related AC isoforms, each containing a NT binding site 
for Gβγ, we examined NT binding versus stimulation of AC6 by Gβγ hotspot mutants. Unlike 
AC5, hotspot mutants of Gβγ displayed both reduced binding to the AC6NT (Figure 11A) and 
prevented conditional stimulation of AC6 (Figure 11B). Thus, Gβγ interactions differ between 
AC5 and AC6. 
Previous work had shown that Gβγ could conditionally stimulate AC5/6 in the presence 
of either Gαs or forskolin (93). We show that the Gβγ hotspot is also required for AC5 and AC6 
conditional stimulation by forskolin (Figure 11C and 11D), suggesting that the requirement for 
the hotspot is due to direct interactions of Gβγ with AC, independent of Gαs. 
Since Gβγ bound to the NT of many AC and the hotspot was necessary for binding to 
the AC6NT but not AC5NT, we screened the other AC NT with wildtype vs. W99A hotspot 
Gβγ to determine the isoform specificity of hotspot necessity for Gβγ/ACNT binding. The 
hotspot mutation of Gβγ caused decreased binding of all non-AC5 NT, although the relative 
effect of W99A varied depending on the AC NT tested (Figure 11E). Thus, the relative hotspot 
necessity for AC NT binding by Gβγ is isoform-specific. 
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Figure 11: Gβγ Hotspot Mutants Interfere with Binding to AC NT, Stimulation of AC6. 
A, Pulldown of GST or GST-tagged AC6NT (2 µM) incubated with 300 nM wild-type Gβγ 
(WT) or the indicated Gβγ hotspot mutants. Elutes from GST pulldowns were analyzed by 
Western blotting.  B, AC activity assay with Sf9 membranes expressing AC6 were stimulated 
with 50 nM Gαs +/- 300 nM Gβγ. C, D, AC activity assay with Sf9 membranes expressing 
AC5 (C) or AC6 (D) were stimulated with either 50nM Gαs or 50µM forskolin +/- 100 nM 
Gβγ. E, Pulldown of GST-tagged AC NT of the isoform indicated (4 µM for 1NT/2NT 
pulldowns, 2 µM for 3NT/9NT pulldowns), incubated with 300nM wildtype (WT) or hotspot 
mutant (W99A) Gβγ. Elutes from GST pulldowns were analyzed by Western blotting. 
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4.4 Pharmacological Targeting of Gβγ Supports a Unique AC5 Regulatory Mechanism 
Compared to Other AC Isoforms. 
In addition to alanine-scanning mutants of Gβγ, we also used a different method of 
targeting Gβγ-AC interactions. The small SIGK peptide has been used previously to disrupt 
select hotspot-dependent Gβγ interactions with effector proteins (177, 206). Addition of SIGK 
prevented Gβγ regulation of several AC isoforms, including Gβγ inhibition of AC1 and 
stimulation of AC2 and AC6 (Figure 12B and 12D). However, SIGK was surprisingly unable 
to block AC5 stimulation by Gβγ, even at higher concentrations of SIGK peptide (Figure 12B 
and 12C). The AC isoform differences from pharmacological targeting of the Gβγ hotspot 
support a unique AC5-Gβγ regulatory mechanism. 
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Figure 12: SIGK Peptide Blocks Gβγ Regulation of AC in an Isoform-Specific Manner. A, 
Sf9 membranes expressing the indicated AC isoform were stimulated with 50 nM Gαs +/- Gβγ 
(50 nM Gβγ for AC1 and AC2; 300 nM for AC5 and AC6). AC assays were in the presence or 
absence of 10 µM SIGK peptide. C, D, SIGK inhibition curves with Sf9 membranes expressing 
AC5 (C) or AC6 (D). AC containing Sf9 membranes were stimulated with 50 nM Gαs +/- 300 
nM Gβγ and the indicated concentrations of SIGK peptide (red) or a control peptide (SIGK 
L9A, black). 
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4.5 Small Molecule Gβγ Inhibitor Gallein Does Not Block AC Activity 
In addition to hotspot Gβγ inhibition via use of the SIGK peptide, novel small molecule 
inhibitors of Gβγ has been developed with varying selectivities. A screen for small molecule 
inhibitors of Gβγ that could compete with SIGK for the Gβγ hotspot resulted in a diverse set of 
nine candidates, with high nanomolar to micromolar IC50’s for blocking Gβγ regulatory 
actions (207). One of these candidates was gallein. Gallein has been shown to inhibit PLCβ2/3, 
PI3Kγ, GRK2, and the GEF pREX1, affecting phenotypes including prevention of heart failure, 
roles in prostate cancer metastasis, and neutrophil movement (207-212). Although that is still a 
fairly nonselective range of effects, gallein does have selectivity in that it is unable to affect 
Gβγ-mediated regulation of ERK1/2, N-type calcium channels, and GIRK channels, according 
to a combination of published work (207) and unpublished observations that have been noted in 
published reviews (213). This inhibition of Gβγ by gallein appears to occur via binding in a 
reversible, noncovalent competitive mechanism at the Gβγ hotspot (214). 
We attempted to test the specificity of gallein for AC isoforms tested against SIGK. 
Based on our results, gallein had no effect on stimulation of AC2, AC5, or AC6 by Gβγ (Figure 
13). The selectivity between AC isoforms shown by the SIGK peptide was not replicated by the 
more specific Gβγ inhibitor gallein; thus, differences in the role of the Gβγ hotspot in 
regulation of AC isoforms are more subtle than differences in Gβγ hotspot mediated regulation 
between different effectors. 
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Figure 13: Gβγ Hotspot Inhibitor Gallein Does Not Block Gβγ Stimulation of AC. A, 
Chemical structures of the small molecule Gβγ inhibitor gallein (Ga), and the small molecule  
control fluorescein (Fl). B, Sf9 membranes expressing AC2 were stimulated with 50 nM Gαs 
+/- 50 nM Gβγ in the presence of gallein (Ga), the hotspot non-interacting small molecule 
analog fluorescin (Fl), or a DMSO control (Ctrl). C, Sf9 membranes expressing AC5 were 
stimulated with 50 nM Gαs +/- 300 nM Gβγ. AC5 stimulated with Gβγ was performed in the 
presence of gallein (Ga), the hotspot non-interacting small molecule analog fluorescin (Fl), or a 
DMSO control (Ctrl). D, Sf9 membranes expressing AC6 were stimulated with 50 nM Gαs +/- 
300 nM Gβγ in the presence of gallein (Ga), the hotspot non-interacting small molecule analog 
fluorescin (Fl), or a DMSO control (Ctrl). 
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4.6 Gβγ Binds to AC5/6 Catalytic Domains 
Although multiple Gβγ binding sites on AC5 were expected, only the AC5NT 
heterotrimer scaffolding site had previously been identified. We assumed based upon homology 
with AC6NT that a second site necessary for activation was likely present in AC5NT. 
However, due to expression issues in E. coli, we have never been able to test this region 
directly (aa residues 195-238). Gβγ interacts with multiple sites in AC2 to promote conditional 
stimulation, including the C1 and C2 catalytic domains (36, 54, 55).  Therefore, we used 
several strategies to determine if Gβγ interacted with the C1/C2 domains of AC5 and AC6.  
Streptavidin pulldowns of biotin-tagged purified Gβγ showed strong interactions with the H6-
tagged C1 domain of AC5 that was independent of the W99A mutation (Figure 14A). 
However, due to nonspecific binding issues, this method could not be used to determine if 
AC5-C2 bound to Gβγ. To overcome this limitation, we performed a Gβγ binding overlay assay 
where the C1 and C2 domains were separated by SDS-PAGE, renatured, and incubated with 
WT or W99A purified Gβγ (Figure 14B, 14C). The detection of AC5-C1 interactions was weak 
but did not reproducibly depend on mutation of W99, similar to what was observed by 
streptavidin pulldowns. A much stronger interaction was observed with AC5-C2 using this 
assay, likely due to its greater capacity for renaturation (data not shown). Thus, Gβγ is capable 
of interacting with all three cytoplasmic domains of AC5. Compared to WT Gβγ, the W99A 
hotspot mutant showed a 2-3 fold decrease in binding affinity for the 5C2 domain (Figure 14C). 
Similarly, Gβγ also bound to the AC6 C1 and C2 domains (Figure 14D). The W99A-Gβγ 
mutant displayed impaired interactions with both AC6-C1 and AC6-C2, with an approximately 
5-6 fold decrease in binding affinity for AC6-C2 compared to WT (Figure 14E). Thus, Gβγ 
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binds to the C1/C2 catalytic domains of both AC5 and AC6, with a high dependency on the 
hotspot for interactions with the C2 domain.  
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Figure 14: Gβγ Interacts with AC5/6 Catalytic Domains. A, Streptavidin pulldown of 300 
nM biotin-tagged Gβγ wildtype or mutant incubated with 500 nM His-tagged AC5-C1. 
Pulldowns analyzed by SDS-PAGE and Western blot. B and D, Far-Western Gβγ assay using 
AC5-C1 and AC6-C2 (B) or AC6-C1 and AC6-C2 (D) immobilized on PVDF membrane and 
probed with Gβγ WT or W99A. C and E, Quantification of relative WT or W99A Gβγ binding 
to AC5-C2 (C) or AC6-C2 (E) domains.  
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4.7 AC5-Gβγ Interactions Depend on Multiple Sites within Gβγ. 
Previously, Yuan et al. have shown that Gβγ can contact PLCβ using the NT of Gβγ 
(residues 23-27) when the hotspot is otherwise occupied, allowing Gβγ to stimulate PLCβ when 
simultaneously bound by a Gα subunit as well as a receptor-independent activator of G protein 
signaling (AGS8) (204). Therefore we wanted to determine if Gβγ uses multiple interaction 
surfaces to regulate AC5 and/or AC6. Mutation of residues 23-27 of the Gβ NT greatly 
impaired the ability of Gβγ to stimulate AC activity, with only marginal effects on binding to 
the AC5/6 NT (Figure 15). Thus, multiple regions of Gβγ are required for regulation of AC5/6 
activity. 
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Figure 15: Mutation of Gβ NT Inhibits Stimulation of AC5/6, but Not Binding to AC5/6 
NT. A and B, Pulldown of GST-tagged AC5NT (A) or AC6NT (B) with purified Gβγ wildtype 
or Gβ(NT23-27)γ mutant. Final concentrations were 2 µM GST-ACNT and 300 nM Gβγ. 
Elutes from GST pulldowns were analyzed by Western blotting. C,D, AC activity assay with 
Sf9 membranes expressing AC5 (C) or AC6 (D) were stimulated with 50 nM Gαs and 
indicated concentration of Gβγ. 
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Endogenous Gαs and Gβγ are readily detectable in immunoprecipitations of Flag-
tagged AC5 from HEK293 cells (95). To determine which surface(s) of Gβγ are required, we 
analyzed the interactions of Flag-tagged AC5 with YN-tagged Gβ (YN-Gβγ) to differentiate 
mutants from endogenous wild-type Gβγ. YN-Gβγ was expressed significantly less than 
endogenous levels, but could clearly be pulled down upon immunoprecipitation of AC5. This 
interaction was not significantly reduced with Gβγ-W99A or Gβγ-NT23-27, but both mutations 
were required to observe a significant reduction in AC5 association (Figure 16). Similar to in 
vitro AC activity assays, both the hotspot and NT surfaces of Gβγ were required to interact 
with AC5 in cells. Therefore, Gβγ regulation of AC5 is not a simple two-site mechanism, but 
rather utilizes multiple surfaces of Gβγ and AC5 for scaffolding and enzyme stimulation.  
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Figure 16: Multiple Sites on Gβγ Are Involved in Binding to AC5 in HEK293 Cells. A, 
Immunoprecipitation of Flag-tagged AC5 and YN-Gβγ wildtype or mutants. HEK293 cells 
were transfected with the indicated plasmids, lysed, and subjected to an immunoprecipitation 
using anti-Flag agarose resin. Associated proteins were analyzed by Western blotting. B, 
Quantification of Flag-AC5/YN-Gβγ IP-Westerns. C, Lysate samples from 
immunoprecipitation of Flag-tagged AC5 and YN-Gβγ wildtype or mutants, with analysis by 
Western blotting to compare expression of YN-Gβγ to endogenous Gβγ. 
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4.8 Summary 
We have explored Gβγ interactions and regulation of AC isoforms, particularly the 
differences in scaffolding versus stimulation of AC5. The Gβγ “hotspot” is necessary for AC5 
stimulation but not solely required for interaction at the AC5NT. This contrasts with AC6, 
where the Gβγ hotspot is required for all known AC6 interaction sites. Furthermore, Gβγ bound 
to a wide variety of AC NTs; hotspot dependent interactions with AC NT varied with the 
isoform of AC. Gβγ hotspot competition by the peptide SIGK blocked Gβγ regulation of 
various differentially regulated AC isoforms, but surprisingly did not affect Gβγ regulation of 
AC5. We also determined that the very selective small molecule Gβγ inhibitor gallein was 
unable to affect Gβγ stimulation of AC2/5/6. Thus, we were restricted to the lessons learned 
from SIGK competition for Gβγ’s hotspot; namely, that AC5 appears to have a unique 
characteristic in how it is regulated by Gβγ. 
 For both AC5 and AC6, Gβγ interacts with all three intracellular domains of AC; NT, 
C1 and C2. The large numbers of interaction sites on AC5/6 mirrors the multiple points of 
contact on Gβγ, as Gβγ NT mutants much like their hotspot counterparts were unable to fully 
stimulate AC5/6. This emphasizes the multiple domains on both AC and Gβγ involved in 
interactions for the stimulatory effect observed, a phenomenon supported by observing 
AC5/Gβγ binding in cells via immunoprecipitation when single surfaces of Gβγ were mutated, 
but not when both the hotspot and NT of Gβγ were disrupted. The AC5 and AC6 interactions 
with Gβγ are summarized in Table 4. Overall, the mechanistic difference of AC5 is that it has 
an NT binding site for Gβγ not directly involved in stimulation, a property not shared by other 
AC isoforms. 
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Table 4: Results Summary of AC5/6 Interactions with Gβγ 
 
AC5 AC6 
Gβγ 5NT 
Binding 
5C1 
Binding 
5C2 
Binding 
AC5 
Stim. 
6NT 
Binding 
6C1 
Binding 
6C2 
Binding 
AC6 
Stim. 
WT Yes Yes Yes Yes Yes Yes Yes Yes 
NT 23-27 Yes   No Yes   No 
W99A  Yes Yes Dec. No No Dec. Dec. No 
M101A  Yes   Dec. No   Dec. 
D186A  Yes   No No   No 
N230A  Yes   No No   No 
H311A Inc.   Yes Inc.   Yes 
Yes = binding or stimulation (Stim.) observed. No = binding or stimulation not observed. Inc. = 
binding or stimulation observed, higher than wildtype (WT). Dec. = binding or stimulation 
observed was significantly lower than that of wildtype. 
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Chapter 5 
Discussion 
 
5.1 Summary of Conclusions 
Based on inhibition curves against all 9 AC isoforms, alleged AC5 inhibitors SQ22,536 
and Ara-A are actually AC5/6 inhibitors. Thus, their use in studying AC5 specific 
physiological roles is questionable, particularly in the terms of congestive heart failure where 
AC6 inhibition in cardiomyocytes may have effects opposite to that of AC5 inhibition. Also, 
allegedly isoform selective AC inhibitors such as NB001 may inhibit cAMP signaling in an 
isoform specific manner in cells without directly targeting the AC itself. These results showed 
the need to complement cell based novel drug screens with precise in vitro characterizations of 
inhibitor candidates. Building upon this concept, a novel AC2 inhibitor from a cell-based 
inhibitor screen was characterized in vitro, showing direct effects with greater inhibition of 
AC2 compared to AC1/5, and a noncompetitive inhibitory mechanism. 
In tandem with study of pharmacological modulators of AC and their isoform 
specificity, I further explored isoform specific aspects of AC regulation by the physiological 
regulator Gβγ. Gβγ binds to a wide variety of AC isoforms, displaying isoform-specific 
variation in the requirement of the Gβγ “hotspot” region in mediating these interactions. In 
addition, whereas hotspot mutants of Gβγ demonstrated the necessity of the hotspot for AC5 
stimulation but not for interactions with the 1-195 aa of AC5 NT, the hotspot was required for 
both AC6 NT binding and stimulation of AC6. Thus, G protein heterotrimeric binding to the 
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AC5 NT does not appear to require the Gβγ hotspot directly, consistent with its coverage in 
interactions with Gαs-GDP. Furthermore, this lack of hotspot necessity is specific to the AC5 
NT at this time. The ability of the SIGK peptide to block Gβγ regulation of AC1/2/6 but not 
AC5 supports a unique AC5 regulatory property. Gβγ NT mutants are unable to stimulate 
AC5/6 in vitro. AC5 and Gβγ were immunoprecipitated from cells even if the Gβγ hotspot or 
NT were mutated, but not if both Gβγ surfaces were mutated. These suggest multiple 
interaction sites on both AC isoforms and the Gβγ regulator. In addition to the AC5/6 NT, Gβγ 
binds to the C1/C2 domains of both AC5 and AC6 in what appears to be a hotspot dependent 
manner, consistent with Gβγ stimulating both of these isoforms via catalytic domain 
interactions. As such, Gβγ stimulates AC5 and AC6 similarly in hotspot-dependent regulatory 
interactions, and the AC5 NT appears to be isoform specific in its separate, hotspot-
independent binding of inactive Gβγ. 
 
5.2 Pharmacological Selectivity of AC5/6 
Results indicate that although SQ22,536 and Ara-A inhibit AC by binding at the 
catalytic site as has been proposed, their inhibition is AC5/6 selective. The lack of selectivity 
for SQ22,536 and Ara-A between AC5 and AC6 is consistent with recent developments on the 
effects of AC inhibitors on cardiac knockout models. Studies have proposed AC5-specific roles 
in chronic heart failure development and in control of heart rate during parabolic flight using 
Ara-A (189, 215). However, in other recent studies, inhibition of cardiac AC activity by 
SQ22,536 and Ara-A is the same in wild-type and AC5 knockout animals (216). Additionally, 
AC5KO animals had lower basal AC activity levels compared to wildtypes, but no change in 
stimulated AC activity levels. This was despite no changes in mRNA expression of the cardiac 
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AC isoforms. As AC5/6 are the predominant AC isoforms in cardiomyocytes, it appears that 
upregulated AC6 activity and wildtype AC5/6 activity were similarly inhibited by Ara-A. 
Similar issues have occurred previously using these inhibitors to identify AC5-specific 
function. Based on work using pharmacological inhibition by SQ22,536, the authors proposed 
AC5 was primarily responsible for cAMP signaling involved in renin secretion in kidney cells 
(217). Later knockout models clarified both AC5 and AC6 were involved in renin secretion 
(218), and additional cAMP signaling roles in the kidney have been specific to AC3 and AC6 
rather than AC5 (219, 220). Our work sheds additional light on the weaknesses of poorly 
characterized inhibitors to ascribe physiological roles to specific AC isoforms. 
Additional off-target effects are also of concern. Ara-A is clinically used under the 
name vidarabine as an antiviral that inhibits DNA synthesis and AMP activated protein kinase 
α-2 (188, 221). While small molecule drugs can be clinically repurposed, there remains the 
concern of off-target effects. Ara-A is an adenosine-like molecule, and the ATP binding sites of 
DNA polymerases and AC are not highly divergent. It is notable that clinical data has resulted 
in vidarabine’s current use being restricted to a limited dose range, and only for treatment of 
viral eye infections. Similarly, SQ22,536 displays AC-independent effects on neurogenesis and 
superoxide production (222, 223). As many ligand-based AC inhibitor screens have been at the 
AC catalytic site, small molecule inhibitors have both been derived from and themselves 
resemble ATP-like compounds. Information on whether known AC inhibitors have any 
reactivity with kinase inhibitors competitive for ATP is also lacking. The many ATP binding 
sites in the human biochemical milieu make for unpredictable off-target effects. 
 
5.3 Characterizing Isoform Specific AC/cAMP Modulation 
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The NB001 inhibitor decreases cAMP in an AC1-dependent manner in cells. However, 
direct inhibition of AC1 in vitro was not observed. Such work shows the drawbacks when 
attempting to characterize drug candidates, particularly AC inhibitors, in cell-based assays. 
Such assays can identify compounds with therapeutic value; irrespective of its actual target, 
NB001 does decrease behavioral symptoms of neuropathic pain. AC1 is involved in such pain 
sensation (224, 225), but also in long-term potentiation aspects of memory (226). NB001 also 
does not have effects on motor function or spatial memory (166), and a similar separation for 
NB001’s inhibition of pain signaling without impairment of anxiety behaviors was observed in 
models of pain induced by irritable bowel syndrome (166, 227). Such behavioral studies are 
consistent with an indirect effect beyond inhibiting AC1 activity. Recent use of NB001 has 
explored allegedly AC1-specific function in long term potentiation in the development of 
chronic pain (228). Thus, it is important to suggest a mechanism or alternative target for 
NB001’s AC1-dependent effects in cells that cannot be replicated in vitro. 
AC1’s role in neuropathic pain is thought to be through a cAMP increase caused by 
calmodulin stimulation of AC1. NB001 inhibited calmodulin-stimulated AC1 activity in cells 
but not that of AC8, which is also stimulated by calmodulin (166). Since we could not replicate 
this AC1 inhibition in cell-free assays, it is worth noting other potential NB001 targets within 
cells. Another kinase activated by calmodulin, CaMKIV, is capable of selectively inhibiting 
AC1 but not AC8 activity in neurons (229). Thus, NB001 stimulating CaMKIV, and 
subsequent AC1 inhibition by CaMKIV is a possible link between an AC1-dependent decrease 
in cAMP and decreased neuropathic pain upon treatment with NB001. Alternatively, the ATP-
like structure of NB001 may be metabolized into an AC1-specific inhibitor product. Such a 
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modification to “activate” NB001 in cells would explain NB001 inhibition of AC1 in vivo but 
not the in vitro membrane assay setting, where such a modifying enzyme was not present.  
Examples such as NB001 highlight the due diligence needed to characterize hits from 
high throughput screens, particularly when such screens are ligand-based. I characterized SKF-
83566 and, to a lesser extent, tranilast after another group identified them as cellular AC2 
inhibitors using a cell-based stimulatory screen, showing that unlike NB001 these hits were 
able to directly inhibit AC2 activity. The characterizations of SKF-83566 demonstrate how to 
use in vitro characterization of AC inhibitor candidates as a supplemental selectivity screen in 
combination with a high throughput virtual or cell-based screen. 
The differences between in vitro and in vivo AC signaling relate to physiological 
regulator effects and functions as well. For AC5/6 and Gβγ regulation itself, initial cell-based 
characterizations were used to determine if the effect was stimulatory or inhibitory, with 
misleading results. Cellular transfection of Gβγ subunits with either AC5 or AC6 suggested 
inhibition of these isoforms (230). However, in hindsight this work’s overexpression of Gβγ 
could regulate any number of targets eventually resulting in inhibition of AC5/6; opening up 
the cell cytoplasm to free calcium ions or activating inhibitory PKC isoforms via PLCβ are two 
potential ways this could happen. Later characterizations of AC5/6 regulation by Gβγ either in 
vitro or in cells with endogenous Gβγ clarified the direct conditional stimulation of Gβγ 
regulation on AC5/6 (93). 
 
5.4 AC5/Gβγ Specificity of Mechanism 
AC5 has a unique interaction site with Gβγ at the AC5 NT. This site, not required for 
regulatory actions, appears to be a scaffolding site for Gαs/Gβγ heterotrimer, while Gβγ is also 
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capable of interacting with the AC catalytic domains for stimulatory effects. Gβγ differential 
effects on AC isoforms already included stimulation of AC 2/4/5/6/7 and inhibition of AC 
1/3/8. Compared to the other AC isoforms, AC5/6 are very closely related, but do have 
differences in their regulation by heterotrimeric G protein subunits. Specifically from this work, 
the observed difference is that the AC6 NT both requires the Gβγ hotspot for binding 
interactions and is necessary for AC6 stimulation by Gβγ, whereas the AC5 NT neither requires 
the Gβγ hotspot for binding nor is necessary for AC5 to be stimulated by Gβγ. AC5 and AC6 
also have differences in their Gα regulatory properties. Gαi inhibits Gas-stimulated AC5 and 
AC6, while only the basal activity of AC5 is Gαi-inhibited. In addition, Gαs stimulation curves 
of human AC5 and AC6 suggested cooperative stimulation of human AC5 with a Hill 
coefficient of 1.4, but negligible cooperation in Gαs stimulation of human AC6 (23). It appears 
that AC5 has unique regulatory properties via both Gα and Gβγ subunits. 
It is worth mentioning that the AC5 NT used in our in vitro GST-pulldown binding 
assays may be missing a binding site analogous to that on the AC6 NT; the purified GST-5NT 
domain consists of aa 1-195 of AC5 (Figure 9A). Some structure prediction programs propose 
that AC5 does not begin its first transmembrane spanning domain until after aa residue 238. A 
region of AC6 NT 77-151, which has been mapped as required for Gβγ stimulation of AC6, 
shares homology with aa 200-238 of AC5. That region of AC5 may be a distal site on the AC5 
NT where Gβγ both binds in a hotspot-dependent manner and is utilized for Gβγ stimulation of 
AC5. This could also potentially explain why purified C1/C2 domains of AC5, even with AC5 
NT with aa 1-195 present, is unable to be stimulated by Gβγ (95). 
At first glance, lack of SIGK competition indicates unique AC5 regulation by Gβγ. AC5 
is not the only effector target of Gβγ with hotspot interactions that SIGK competition cannot 
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disrupt; voltage-gated calcium channel regulation by Gβγ is also unaffected by SIGK (206). 
However, it is unclear precisely why SIGK is unable to block Gβγ stimulation of AC5, but able 
to disrupt regulation of other AC isoforms. According to the model of heterotrimeric G protein 
“breathing”, heterotrimeric interactions exist between Gβγ and both the Gα NT as well as the 
Gα Switch 2 helix. This allows a certain degree of heterotrimer flexibility, and has been 
supported by significantly stronger binding between the G protein subunits when both 
interactions are combined relative to when either Gα region is mutated (231, 232). It is possible 
that AC5/Gβγ interactions are less “breathable”, decreasing the ability for SIGK to compete for 
the hotspot. The SIGK peptide interacts with residues on 6 out of 7 blades of the WD40 barrel-
like structure at the hotspot (207), but AC5 interactions with other areas such as Gβ NT 
residues 23-27 may help to overcome competition by SIGK. Gβγ residues 23-27 are utilized for 
regulation of PLCβ (178), and for interaction with AGS8 under an alternative signaling 
mechanism when the hotspot is otherwise occupied (204). Such an alternative signaling 
mechanism could also explain AC5-specific utilization of Gβ NT 23-27 when mutation of this 
area affected Gβγ stimulation of both AC5 and AC6. PI3K appears to interact with the Gβ NT 
at residues 31-45, another unexplored region for AC/Gβγ interactions (233). AC5 may also 
interact more strongly with hotspot residues on blade 6 of Gβγ, a region that does not contact 
SIGK. None of the alanine-substitution hotspot mutants of Gβγ used in the results shown here 
are located on blade 6 as well. 
Since only the NT of AC5/6 differ in their dependency on the Gβγ hotspot for 
interactions, it is possible that loss of SIGK efficacy is a 5NT mediated effect. However, we 
show that AC5 and AC6 have multiple interaction sites with Gβγ. This is analogous to AC2, 
the AC isoform most thoroughly mapped for Gβγ binding. In addition to our observed binding 
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of Gβγ to AC2NT, binding sites have been mapped to the C1 domain and C2 domains of AC2 
(36, 52, 54, 55). These identified sites are summarized in Figure 17. AC5/6 show 65% 
homology to the site located within the C1a domain of AC2 (aa 339-360), while sites located 
within the C1b and C2 domains of AC2 are poorly conserved or not present in AC5/6 (55). The 
AC2 aa 493-514 sequence is significant in that it is a so-called PFAHL motif that was required 
for stimulation of AC2 by Gβγ; it shows only 26% homology with AC5, but is part of the very 
flexible C1b region of the C1 domain. Although the AC2 NT requirement for stimulation of 
AC2 by Gβγ is not ruled out, this supports stimulation by Gβγ of AC requiring C1/C2 catalytic 
domain modulations. Similar to AC5, AC2 has a so-called QEHA motif which is a binding site 
for Gβγ that was not required for stimulation of AC2 by Gβγ. However, unlike the AC5 NT 
heterotrimer binding site, the AC2 QEHA motif is located on the C2 domain. Therefore, even if 
other AC isoforms can scaffold inactive G proteins like AC5 can at its NT, the location of that 
anchoring may be isoform specific. 
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Examining the C1/C2 crystal structure, it appears that there are Gβγ binding sites for 
AC5 on opposite ends of the catalytic shell. AC5 has the longest NT by amino acid sequence of 
all the isoforms, but even ~200 amino acids is not sufficiently long to realistically wrap around 
the entire C1/C2 catalytic core. It has been shown previously in cells that AC5 and AC2 are 
able to form functional AC heterodimers (234). This AC5/AC2 heterodimer was also more 
sensitive to stimulation by Gαs or forskolin, possibly suggesting enhanced Gβγ mediated 
potentiation of AC5/2 signaling. Furthermore, previously observed cooperative stimulation of 
AC5 by Gαs can be explained by the presence of AC5 dimers (23). In such a situation, it is 
unclear physiologically whether AC5 would homodimerize or produce heterodimers such as 
Figure 17: Summary of Identified Gβγ Binding Sites on AC2. C1 domain is yellow, C2 
domain is silver. C1a interacting sequence is pink. C2a KF loop is cyan. QEHA domain is 
orange. AC5 Gαi binding site is red, Gαs binding site is green. C1b, where PFAHL motif is 
located, is disorded and its general location is indicated by the purple circle. Note that the areas 
conserved between AC5 and AC2, namely C1b and C2a regions such as the KF loop (QEHA 
domain is not conserved), are either too dynamic for crystallization or near where the plasma 
membrane would be. 
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AC5/AC2, since both are capable of stimulation by both Gαs and Gβγ. In addition, AC6 
fragments have been able to immunoprecipitate AC1, AC2, or AC5 from cells, suggesting the 
possibility of AC5/6 heterodimers (235). In such cases, since AC2/5/6 are all stimulated by Gβγ 
to some degree, AC5 NT scaffolding inactive Gαs/Gβγ heterotrimer could facilitate Gβγ 
stimulation of a AC heterodimer through spatial proximity of Gβγ to the C1/C2 catalytic core, 
with active Gβγ stimulating AC through a combination of interactions with the C1 domain of 
one AC isoform and the C2 domain of a second isoform. In summary, the proposed mechanism 
of Gβγ regulation of AC5 is inactive Gαs/βγ heterotrimer is scaffolded to AC5 NT aa 66-137, 
and following activation the G protein subunits interact with the AC5 catalytic domains to 
enhance catalytic activity (Figure 18). For both AC5 and AC6, stimulation by Gβγ may involve 
interaction with distal NT sites, and/or close vicinity to AC catalytic domain regions such as 
C1b and C2a that have sections near the plasma membrane.  
 
 
Figure 18: Proposed Mechanism for AC5 NT Scaffolding and AC5 Stimulation by Gβγ. 
Inactive G protein heterotrimer is scaffolded to the AC5 NT (left). After G protein activation, 
Gαs stimulates AC5 at the C2 domain, while Gβγ stimulates AC5 at the plasma membrane by 
interacting with the 5C1/5C2 domains in a hotspot-dependent manner, and possibly interaction 
with a distal 5NT site (right). 
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Similarly, the distal C-terminus of GIRK1 also anchors Gβγ, but is not required for Gβγ 
regulation of GIRK1; it was proposed that such anchoring is for localized recruitment of Gβγ 
(69). As another example, the scaffolding protein WDR26 binds both Gβγ and PLCβ2, 
mediating Gβγ regulation by recruitment of PLCβ2 from the cytosol to the plasma membrane 
(236). Although currently such an anchoring function in AC appears to be specific to the AC5 
isoform, other AC isoforms may anchor Gβγ independent of any regulatory role. Gβγ binds to 
AC9NT in a hotspot-dependent manner in our pulldown binding assays, even though Gβγ may 
lack a direct regulatory effect on human AC9 (25, 237). 
 
5.5 Proposed Function of AC5 NT Scaffolding 
The function of an AC NT on cAMP producing activity could be to 1) localize 
regulators such as Gβγ nearby the C1/C2 domains, or 2) through direct interaction of the NT 
with the C1/C2 domains. Further AC isoform specificity is brought by indirect AC regulator 
function in a way besides stimulation or inhibition of cAMP production. For example, 
heterotrimeric G proteins bound to the AC5 NT may undergo effects similar to those observed 
for PKC anchored to AKAP79. When bound to AKAP79, PKC’s regulatory profile is modified 
(238). Not surprisingly, an AKAP anchoring PKA and a downstream target significantly 
enhanced the likelihood of that target’s phosphorylation by PKA (239). In terms of AC5/6, this 
implies a potential AKAP-scaffolded effect on feedback inhibition by PKA. Localized ion 
channels such as Na+/H+ exchanger 1 can shield AC from changes in pH; thus, another 
interpretation is that the AC5 NT protects G protein heterotrimers from undesired stimuli (240). 
Gβγ has a wide variety of physiological targets beyond AC; anchoring to the AC5 NT could 
also restrict heterotrimeric G protein regulation to AC and local pool of targets. That cardiac 
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overexpression of Gαs results in AC-independent activation of L-type calcium channels 
supports this idea (241). Similarly, AC8 NT aids in enhanced actin based signaling at the 
plasma membrane that is restricted to AC8 movement in cholesterol-enriched domains (242). 
In cells, both heterotrimeric G protein subunits were needed to see full AC6 stimulation 
by the Gαs-coupled GPCR agonist isoproterenol (93). Since AC5 and AC6 are both stimulated 
by Gβγ, but only AC5 has a heterotrimer scaffolding site, our proposed AC5 scaffold-primed 
signaling adds another dimension to the composition of isoform-specific signaling complexes. 
It is of interest to consider whether a localized cAMP signaling pathway involves AC5, which 
could self-scaffold a Gαs heterotrimer, or AC6, which may rely on a scaffolding protein to 
provide heterotrimeric G protein. Supporting this idea, through a Gβγ dependent process, EP1 
receptors are able to induce D1 receptor signaling stimulating AC7; it was shown that 
disruption of such complexes produced separate signals that stimulated AC6 activity (243). 
Complexes with β2-AR have been identified that include heterotrimeric G protein, AC, 
PKA and an opposing PP2A phosphatase, and Cav1.2 L-type calcium channel to be targeted by 
PKA (244). AKAP79/150 interacts with upstream β-AR receptors, as well as AC5/6 at their NT 
(103, 104). Fully functional AC2/AKAP79 signaling complexes are involved in signaling 
produced by the hormone relaxin (245). Similarly, a larger complex facilitated by AKAP79/150 
may contain all necessary components for signaling from a Gαs-coupled GPCR to PKA and 
downstream effectors via AC5 generation of cAMP (Figure 19). AC5 would provide Gαs 
heterotrimer to AKAP79/150 complexes, which are capable of β-AR/AKAP79/AC5 mediated 
blockade of TRPV1 channel desensitization in HEK293 cells and PGE2/AKAP150/AC5 
mediated blockade of TRPV1 channel desensitization in mouse dorsal root ganglia (108). 
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5.6 Broader Potential Roles for AC Scaffolded Complexes 
It is possible that G protein anchoring sites such as the AC5 NT are important for 
transmission of isoform specific trafficking information for signaling complexes including AC5 
and heterotrimeric G proteins. The idea of localized signaling complexes involving AC for 
cAMP production has been proposed for some time (202). A combination of 
immunoprecipitations and BRET studies showed a complex between β2-AR receptors, AC2, 
and heterotrimeric G protein subunits that was stable in the absence or presence or receptor 
stimulation, and that was maintained before transportation to the plasma membrane, indicating 
that AC/G protein complexes are preformed (246-248). Specifically, AC2 and GPCRs initially 
formed into a complex at the ER, followed by the associated G protein heterotrimer. 
Furthermore, isoprenylation of the γ subunit of Gβγ is necessary for its plasma membrane 
Figure 19: Potential Role for AC5NT/Gβγ Scaffolding in Signaling from AC5 Complexes. 
Inactive G protein heterotrimer may scaffold to the AC5 NT as part of larger GPCR/G 
Protein/AC5/cAMP signaling complexes, such as those formed by AKAP79. 
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targeting, but heterotrimer formation with a Gα subunit is also required (249). Thus, the 
appropriate G protein heterotrimer may be needed for correct localization of associated GPCRs 
and ACs. 
AC/G protein scaffolded complexes may integrate the formation of AC dimers. As 
mentioned above, functional AC5/2 heterodimers in cells were more sensitive to stimulation by 
Gαs or forskolin (234). Complexes consisting of β2-AR, D4DR, heterotrimeric G proteins, and 
AC2 have been functionally identified in cells via immunoprecipitation and BRET (250). This 
complex showed increased BRET signal between Gβγ and AC2 from isoproterenol stimulation 
of β2-AR, but not from dopamine stimulation of D4DR; this is in contrast to dogma that Gβγ 
mediated stimulation of AC2 comes from Gαi coupled GPCRs like the D4DR (19). Since these 
are proteins expressed via cell transfection, AC5/AC2 dimers for 5NT scaffolding of Gαs/Gβγ 
heterotrimer may be required for stimulation of AC2 by Gαs-coupled Gβγ.  
 
5.7 AC5 vs. AC6 Complex Signaling 
It is worth noting that while AC5 and AC6 are both highly expressed in 
cardiomyocytes, they have differing physiological relevance with regards to cardiac stress-
induced hypertrophy, handling of induced calcium release, and cardiac repolarization/store 
reuptake (251). AC5 and AC6 expression in cardiomyocytes also have visible differences in 
localization (252). Differential PDE4 expression can compartmentalize cAMP signaling, with 
different cardiovascular cell types having varying PDE4 level changes to produce specific 
phenotypic effects (253). Such specificity suggests localized AC/PDE pairs to dynamically 
control cAMP accumulation. 
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Adrenergic receptors, heterotrimeric G proteins, and AC2/5/6 have all been found in 
cardiomyocytes at the nuclear membrane with intact cAMP signaling capability; although 
complex formation was not directly shown, signaling was β-AR isoform specific (254). AC5 
but not AC6 associates with mAKAPβ in the heart at the nuclear membrane, providing AC5 
specific hypertrophic signaling near T-tubules including AC5-specific feedback inhibition by 
PKA (113). AC5 self-scaffolding heterotrimeric G protein may be needed in such a complex 
for proper signaling from adrenergic GPCRs at the T-tubule, as RNAi disruption of mAKAPβ 
prevented adrenergic-stimulated cardiac hypertrophy (112). Similarly, AC5 but not AC6 
knockouts resulted in loss of sympathetic adrenergic signaling, and prevention of chronic heart 
failure state induced via aortic stress band (128, 129, 141). Pathological hypertrophic signaling 
in the heart muscle is needed for such a heart failure state. AC5 knockout also results in 
decreased stress-induced aging of the cardiomyocyte, a phenotype that may be due to an 
increased Akt (130, 131). AC5 knockouts include disruption of parasympathetic Gαi based 
signaling as well (128), although Gαi ability to scaffold to the AC5 NT is significantly weak 
compared to Gαs (95). Notably, Gαi regulation of cardiac AC5 can be receptor independent 
(255). Although an AC5 specific effect, it is unclear if 5NT scaffolding is involved in Gαi 
effects on AC5. 
Initial development of chronic heart failure is associated with increased GRK activity 
(another potential Gβγ target), uncoupling of β-adrenergic receptor signal, and notably in the 
context of this manuscript, decreased AC6 mRNA (256). In contrast to AC5, AC6 knockout 
increases heart failure mortality in animal models (142, 143), and AC6 expression is actually 
beneficial in preventing stress-induced development of heart failure (257, 258). Many of these 
benefits from AC6 expression are replicated using a catalytically inactive mutant (259). Both 
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AC5 and AC6 have NT binding to AKAP79, in a complex strongly associated with both 
adrenergic signaling and cardiac calcium handling (103). In the context of our results, AC5 NT 
specific assembly of adrenergic/AKAP79 signaling complexes is an interesting possibility. 
Caveolin versus noncaveolin distribution of AC isoforms also involves signaling 
complexes with different functions. Isoproterenol or forskolin, but not other Gαs-coupled 
receptor agonists, stimulate cAMP production in an AC6-dependent manner in cardiomyocytes 
(260). This selectivity for AC6 may result from AC6 localization in caveolae; transportation of 
β2-AR out of such caveolae caused decoupling of that receptor (and associated agonists) from 
AC6 stimulation (260, 261). Nitric oxide inhibition of AC6 in cardiomyocytes has similar 
dependency on caveolin-based AC6 complexes (262). AC6 or AC8 regulation by the effects of 
capacitive calcium entry also requires isoform specific complexes in cholesterol rich domains 
(263, 264). Caveolae are also responsible via maintenance of signaling complexes for 
cardiomyocyte protection from ischemic damage; such protection was lost with disruption of 
caveolae and caveolin-1 protein (265). Isoform specificity in Gβγ regulation of AC5/6 via 
caveolin versus noncaveolin localization was not studied, but cannot be ruled out since Gβγ is 
unable to directly stimulate soluble C1/C2 domains of AC5 (95). 
 
5.8 AC5/6 Physiology and Potential AC/Gβγ Complex Roles 
Gβγ is limited in the cell, and may be competed for by various Gα subunits in 
cardiomyocytes (266). The Gαs to Gαi ratio in a heart failure risk state, for example, can be 
between 1:10 and 1:40 (267). Scaffolding on AC of Gαs and Gβγ could maintain local pools of 
Gαs for adrenergic signaling. One of the AC5 heart knockout models had approximately 60% 
loss of Gαs concentration (141). Loss of AC5 could also mean loss of G protein that is 
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otherwise scaffolded and used for signaling in cardiac stress-induced hypertrophy. Treatments 
for preventing heart failure that target Gβγ typically focus not on Gβγ regulation of AC but 
rather effects on β-AR desensitization via Gβγ recruitment of GRK2 and PI3K (268). Cardiac 
and adrenal gland blockade of adrenergic signaling through gallein inhibition of Gβγ, which we 
have shown does not affect AC2/5/6 activity, attenuated β-adrenergic dependent development 
of heart failure in cardiomyocytes (269). Thus, AC activity independent functions such as 
scaffolding may be relevant to Gβγ signaling in progression of heart failure. 
Beyond AC5/6 and G protein roles in heart failure development, there is also a Gβγ-
dependent AC sensitization phenotype seen in neuronal tissues (37, 270). This sensitization, or 
enhanced AC stimulation by Gαs-coupled receptors following prolonged activation of Gαi-
coupled receptors, required the presence of Gβγ subunits (271). AC5 sensitization is also 
closely related to AC5-specific opioid dependency/withdrawal behaviors that have been 
disrupted in AC5 knockout models (126). This Gβγ effect appears to be more organizational in 
nature rather than direct interactions with Gαs; Gαs was needed for sensitization of AC5, and 
blocking Gβγ prevented AC5 sensitization, but Gαs/Gβγ interactions were not required (272). 
This supports an indirect function of Gβγ on AC5 sensitization; Gβγ mediated construction and 
trafficking of AC5-specific signaling complexes as suggested above is one such explanation. 
AC/G protein heterotrimer signaling can also be hijacked in cases of pathological 
invasion, considering cAMP signaling involvement in so many cellular functions. One example 
is the bacteria Bartonella henselae and its BepA protein that is secreted as a result of 
endothelial cell invasion. Release of BepA in endothelial cells results in pathological anti-
apoptotic effects that are associated with increased cAMP (273, 274). BepA’s effects were 
shown to occur via conditional stimulation of AC2/7 in the presence of Gαs, in a mechanism 
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very similar to that employed for conditional stimulation of AC isoforms by Gβγ, including that 
forskolin also was sufficient for BepA to increase cAMP via AC stimulation (275). 
 
5.9 Future Directions—AC Inhibitor Development 
There are limited explanations for what determines isoform selectivity of the AC5/6 
inhibitors studied to date, considering the conservation of the AC catalytic site. The C1 α1 
structural helix is a rare region of lack of isoform conservation; as noted previously, this 
subdomain not only is closely homologous only between AC5/6, but is less homologous for 
isoforms the inhibitors are least potent on, such as AC8/9 (1). This helix is involved in metal 
chelation during cAMP synthesis. As such, designing inhibitors that can either interact with this 
helix or that have metal chelating properties are one avenue for ligand-based AC5/6 inhibitor 
optimization of potency. One published example is the inhibitor PMC-6 (169), but such a 
strategy should also work with optimizing novel non-adenine based small molecules. 
This work further studied AC inhibitors that, for the most part, inhibit AC by 
interactions within the catalytic pocket. This may be one reason for the difficulties in finding 
highly potent non-ATP like small molecule inhibitors. For further AC5/6 inhibitor discovery, 
the Gαi binding site on the C1 domain is a potential alternative therapeutic target site. This may 
provide novel AC1/5/6 inhibitors, as those are the isoforms inhibited by Gαi binding. Further 
selectivity may occur depending on whether inhibitors identified can discriminately involve AC 
NT in the bounding inhibitory conformation. 
In addition to strategies for finding novel isoform selective AC inhibitors, current 
inhibitors can be used in research to further characterize isoform specific physiological roles by 
pharmacological inhibition of AC5/6. For example, although AC5 and AC6 are the most highly 
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expressed isoforms in cardiomyocytes, AC4 and AC9 are also expressed in lesser amounts. 
Despite lower expression, AC9 does have some function in cardiac repolarization. Specifically, 
AC9 is involved in a complex with the ion channel KCNQ1 and AKAP Yotiao in a complex 
that mediates PKA phosphorylation of KCNQ1 repolarization (109-111). Disruption of such a 
complex results in phenotypes resembling long QT syndrome, an abnormal heartbeat. In 
cardiomyocytes, use of the AC5/6 inhibitors and a combination of wildtype vs. AC4/9 
knockout animals could be used to further characterize the necessity and/or sufficiency of AC 
isoforms in cardiac calcium handling, stress responses, and contractile control. 
 
5.10 Future Directions—AC/Heterotrimeric G Protein Regulation 
It is interesting that 5NT was identified as the least hotspot-dependent binding site of 
the AC NT tested. AC9 has no clear effects on its activity by Gβγ, so it is surprising that the G 
protein subunit’s binding to 9NT was so affected by hotspot mutation. Further study is needed 
to understand the significance of hotspot-dependent Gβγ interactions with AC9, and whether 
the 9NT serves as a scaffold to anchor Gβγ for other effectors similar to the function of 
WDR26 (236). 
In the AC5/Gβγ regulatory mechanism proposed, a lot of assumption is placed upon the 
likely 5NT distal binding site that may be required for stimulatory effects. Ways to confirm this 
site has a similar function to the 6NT binding site for Gβγ will be required to clarify that the aa 
66-137 scaffolding site on 5NT is not the only AC5 NT region involved in Gβγ function. 
Most importantly, via immunoprecipitations, multiple interactions between AC5 and 
Gβγ have been shown. However, despite much discussion above about AC and Gβγ 
involvement in larger signaling complexes, these have not been shown directly yet. Further 
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work should examine the dynamics of AC5/Gβγ interaction in cells. In addition, showing AC5/ 
Gβγ dependent formation of complexes in physiologically relevant cellular models can clarify 
the exact effects of AC5 specific heterotrimeric G protein scaffolding, and the selectivity of 
such scaffolding in AC isoform selective cAMP signaling. 
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